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Chronic, low-grade inflammation during obesity is associated with the development of 
metabolic dysfunction.  The NLRP3 inflammasome is assembled in response to cellular 
stressors and leads to cytotoxic cytokines IL-1β and IL-18 production, which implicates 
the NLRP3 inflammasome in inflammatory conditions, including type 2 diabetes.  
Tocotrienols are antioxidant and anti-inflammatory forms of vitamin E.  Delta-tocotrienol 
(dT3) displays NF-κB inhibitory and anti-oxidant abilities, and is easily isolated from the 
Annatto plant.  My primary aim was to determine whether dT3 inhibits NLRP3 
inflammasome activation and to compare the extent to which dT3 inhibits NLRP3 
inflammasome with other tocotrienol forms, i.e. alpha-tocotrienol (aT3) and gamma-
tocotrienol (gT3).  The second aim was to investigate the role of dT3 in NF-κB priming 
and reactive oxygen species (ROS) production, two major signaling pathways for NLRP3 
inflammasome activation.  To determine the inflammasome activation, J774 
macrophages (iJ774) that stably overexpress an inflammasome reporter were pretreated 
with dT3, aT3, and gT3 and stimulated with lipopolysaccharide (LPS)/nigericin.  
Inflammasome activation was measured through Gaussia luciferase activity (iGLuc), IL-
1β production, and caspase-1 and iGLuc immunoblotting.  Raw 264.7 macrophages 
 
 
pretreated with dT3, aT3, and gT3 were stimulated with LPS.  We measured 1) gene 
expression of down-stream targets of NF-κB (Nlrp3, Tnf-α, IL-1β, IL-18) by qPCR and 2) 
degradation of inhibitory protein of NF-κB (IκBα) by Western blot.  Raw 264.7 
macrophages pretreated with dT3, aT3, and gT3 were stimulated with LPS/nigericin and 
ROS production was measured using an ROS-sensitive florescent probe.  Results show 
that 1) 0.5-5 μM dT3 pretreatment inhibited NLRP3 inflammasome activation and IL-1β 
production; 2) 1 μM dT3, aT3, and gT3 pretreatment inhibited NLRP3 inflammasome 
activation and IL-1β production; 3) 1-2.5 μM dT3 inhibited NF-κB activation; 4) 1 μM 
dT3, aT3, and gT3 pretreatment diminished NF-κB activation in macrophages; and 5) 1 
μM dT3, aT3, and gT3 decreased ROS production in LPS/nigericin treated macrophages.  
These studies demonstrated that tocotrienols (dT3, aT3, gT3) lowered NLRP3 
inflammasome activation in macrophages through inhibition of NF-κB activation and 
ROS production with an apparent efficacy of gT3>dT3>aT3.  It suggests that inclusion of 
dietary tocotrienols may constitute a novel dietary strategy to attenuate and/or prevent 
pathogenic progression of obesity.  
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CHAPTER 1. LITERATURE REVIEW 
 
1.1 Introduction 
Inflammation has traditionally been considered as swelling, fever, pain, and 
redness as a tissue response to injury (1).  Inflammation can be beneficial during wound 
healing and infections, but low-grade chronic inflammation can wreak havoc on the body 
and its metabolic processes.  Obesity, insulin resistance, and inflammation were first 
connected in 1901, when Williamson (2) found that the anti-inflammatory compound 
salicylate improved glucose control in diabetes.  Since then, evidence has continued to 
accumulate that links metabolic disease with chronic low-grade inflammation.  The 
effects of chronic inflammation during obesity are wide-spread.  Obesity induces 
inflammatory changes in liver, muscle, the hypothalamus, pancreatic islets, and adipose 
tissue (3).  Inflammation plays a role in overfeeding and energy expenditure (4).  
Inflammation is associated with atherogenesis and endothelial dysfunction (5,6), NASH 
(7) and liver fibrosis (8), and renal dysfunction (9).  Inflammation may mediate the 
development of obesity-induced insulin resistance (10).  Ameliorating inflammation has 
thus been therapeutically targeted for ameliorating the metabolic consequences of 
overweight and obesity and an unhealthy diet.  Inflammation has also been targeted due 
to its central role in many chronic inflammatory diseases.  It is indeed critical to 
determine the molecular mechanisms that connect obesity, inflammation, and metabolic 
dysfunction.   
During chronic inflammation, there are many processes at work that lead to 
metabolic dysfunction.  In the obese state, elevated levels of free fatty acids (FFAs), 
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lipopolysaccharide (LPS), peptidoglycan, and bacterial DNA among other signals initiate 
inflammatory gene transcription (11).  Some theorize that the pro-inflammatory cytokines 
secreted from adipose lead to chronic inflammation and impairs both insulin signaling 
and mitochondrial function, and worsens cardiovascular disease risk (12).  Endoplasmic 
reticulum (ER) stress, hypoxia, and lipotoxicity can be increased by obesity and lead to 
inflammation, and appear to be critical in the impairment of insulin resistance (11). 
Inflammasomes are multimeric protein complexes studied for their role in 
inflammatory diseases and in mediating the complications of metabolic syndrome.  There 
are many families of inflammasomes.  They generally are comprised of a sensor 
molecule, ASC (apoptosis-associated speck-like protein containing a carboxy-terminal 
CARD) and caspase-1 (13).  Inflammasomes detect danger signals through the sensor 
molecules.  These signals include exogenous pathogen-associated molecular patterns 
(PAMPs) and endogenous damage-associated molecular patterns (DAMPs).  Upon signal 
detection, the sensor molecule triggers the ASC, which cleaves pro-caspase-1 to caspase-
1 (13).  The cleavage of caspase-1 is a key event in the activation of the inflammasome. 
Next, the inflammasome will be discussed—its mechanism of activation and effecting 
factors, its role in metabolic disease, and dietary factors modulating the inflammasome. 
 
1.2 NLRP3 Inflammasome 
The NOD-like receptor family, pyrin domain containing 3 (NLRP3) 
inflammasome is one of the more widely studied inflammasomes, particularly because of 
its wide range of activators.  The amino-terminal death fold domain, central NACHT 
nucleotide binding domain, and carboxy-terminal leucine-rich repeats (LRRs) distinguish 
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the NLRP3 inflammasome from other inflammasomes (14).  As with other 
inflammasomes, the NLRP3 inflammasome is signaled through DAMPs or PAMPs.  
NLRP3 inflammasome requires two steps: 1) a priming step that induces NLRP3, pro-IL-
1β, and pro-IL-18 gene transcription, and 2) an activating step in which the 
inflammasome is assembled and caspase-1 is activated (13).  This is completed through 
innate immune signaling or cytokine receptors (13).   
 
Figure 1. Structure and assembly of the NLRP3 inflammasome. In response to 
cellular stressors, the components of the NLRP3 inflammasome are assembled and 
activate caspase-1, which cleaves pro-inflammatory cytokines pro-IL-1β an pro-IL-18 to 
IL-1β and IL-18 (15). 
 
Upon NLRP3 inflammasome activation, the cleaved caspase-1 will cleave the 
pro-inflammatory cytokines pro-interleukin-1β (pro-IL-1β) and pro-interleukin-18 (pro-
IL-18) into their active forms, interleukin-1β (IL-1β) and interleukin-18 (IL-18).  After 
release from the cell, these cytokines perpetuate the inflammatory signal and mediate the 
inflammatory response.  IL-1β and IL-18 have far-reaching actions in the body, and are 
implicated in the development of acetominophin-induced hepatotoxicity, macrophage 
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migration in atherosclerosis, and the development of insulin resistance (8,16,17).  The IL-
1 family of cytokines, which includes IL-1β, are an essential mechanism of the innate 
immune system to protect against infections (18).  These cytokines recruit macrophages 
and other immune cells to attack invading pathogens.  IL-1β is a critical target for auto-
inflammatory syndromes, and these diseases respond to blocking IL-1Ra, the IL-1 
receptor antagonist (18).  Auto-inflammatory conditions include such diseases as familial 
Mediterranean fever, cryopryin-associated periodic syndromes, Muckle-Wells syndrome, 
and neonatal onset multisystem inflammatory disease (18). 
The NLRP3 inflammasome has functions beyond those carried out by IL-1β and 
IL-18 (19).  NLRP3 inflammasome activation is also involved in pyroptosis, a type of 
cell death distinct from apoptosis (19).  Besides cleavage of IL-1β, caspase-1 is involved 
in activating lipid biogenesis and inhibiting glycolysis during sepsis and pyroptosis (20-
22).  The inflammasome clears bacteria such as Salmonella enterica in an IL-1β- and IL-
18-independent manner and contributes to infection control (19).  Caspase-1 participates 
in the cleavage of so-called “leaderless proteins,” such as high mobility group box 1 
(HMGB1), a DAMP (19).  Caspase-1 inhibits glycolysis by impairing the enzymatic 
ability of glyceraldeyde 3-phosphate during infectious invasions (19).  Denes et al. (23) 
identified 121 substrates caspase-1 acts upon. 
The NLRP3 inflammasome can be activated by a variety of exogenous and 
endogenous substances.  Exogenous activators include asbestos (24), silica (24,25), 
maitotoxin (26), sendai virus, influenza virus, adenovirus, Saccharomyces cerevisiae, 
Candida albicans, Shigella flexneri (27), Salmonella typhimurium (28), Escherichia coli 
(29), Staphylococcus aureus (26,29), Bacillus anthracis (30), Listeria monocytogenes 
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(26), ricin toxin (31), and nigericin (26,32).  Numerous endogenous activators include 
monosodium urate (MSU) (elevated in gouty arthritis) (27,33), calcium pyrophosphate 
dehydrate (elevated in calcium pyrophosphate deposition disease) (33), endogenous ATP 
(26,34), TNF-α (35), IL-1β (35), angiotensin-II (36), uric acid (27,34), high glucose (27), 
amyloid-β-fibrils (elevated in Alzheimer’s disease) (27).  Cytokines such as TNF-α and 
IL-1β that are secreted in response to the NLRP3 inflammasome also activate the 
inflammasome, and thus may participate in a positive feedback loop (35).  Necrotic cells 
serve as an internal danger signal for the NLRP3 inflammasome (9).  Due to its wide 
spectrum of activators, the NLRP3 inflammasome becomes active in a wide number of 
conditions. 
NLRP3 inflammasome activation is involved in many auto-inflammatory 
conditions (35).  Fibrosis involves the chronic activation of the NLRP3 inflammasome, 
which perpetuates damage through the synthesis of collagen and extracellular matrix 
protein (37).  The NLRP3 inflammasome is implicated in pulmonary inflammatory 
diseases and links air pollutants to lung cancer and fibrosis (24), and silica-induced 
pulmonary fibrosis (25).  Moreover, the NLRP3 inflammasome is involved in the 
development of cerebral malaria (38) and damage from UVB irradiation.  The NLPR3 
inflammasome provides the link between high glucose levels in metabolic (27) as well as 
amyloid-β-fibrils in Alzheimer’s disease, and MSU and uric acid crystals in gout (39).  
Oslowski et al. (39) demonstrate that glucose toxicity and oxidative stress lead to 
endoplasmic reticulum (ER) stress and NLRP3 inflammasome activation.  On the other 
hand, the NLRP3 inflammasome has beneficial activity during exercise.  Acute exercise 
induces ROS production leading to NLRP3 activation and mitophagy to ameliorate 
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myocardial injury through clearance of damaged mitochondria and suppress further ROS-
induced damage (40). 
NLRP3 inflammasome is active in many different types of cells, including 
monocytes and macrophages (41), T cells (42), myofibroblasts (43), keratinocytes 
(44,45), and hepatic stellate cells (8).  Lebeaupin et al. (46) demonstrated the NLRP3 
inflammasome is active in non-myeloid cells, specifically hepatocytes.  Unlike other cell 
types, blood monocytes constitutively express the NLRP3 inflammasome during the 
resting state, and require only one signal (18).  Due to its large number of activators and 
cells in which it is active, the mechanisms of NLRP3 inflammasome activation are yet to 
be fully delineated. 
 
1.3 NLRP3 Inflammasome Activation 
The NLRP3 inflammasome assembly involves two steps: a priming step and an 
activating step (47,48).  The priming step is necessary but not adequate to activate 
NLRP3 inflammasomes (49).  This requirement for a priming step is another 
characteristic of the NLRP3 inflammasome that sets it apart from other inflammasomes 
(50).  Pattern recognition receptors (PRRs) participate in NLRP3 inflammasome priming, 
in particular through toll-like-receptor (TLR) signaling (3,51-53).  PRRs, including 
TLR4, are necessary for the development of insulin resistance due to high fat diet-(HFD) 
induced obesity (3).  Priming the inflammasome increases gene expression of the 
cytokines, pro-IL-1β and pro-IL-18, as well as expression of NLRP3 inflammasome, and 
may be signaled through TLRs (26).  TLRs activate nuclear factor κB (NF-κB) signaling 
(3) through TNF-α and TLR ligands to increase NLRP3 inflammasome activation (35).  
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NF-κB acts up-stream of ASC to increase NLRP3 inflammasome activation (49).  LPS 
up-regulates inflammasome gene expression in the liver through TLR4 signaling (7).  
Extracellular and endosomal PAMPs, including LPS, signal through TLRs to increase 
pro- IL-1β synthesis (54).  In the obese state, elevated free fatty acids, microbial LPS, 
peptidoglycan, bacterial DNA, and endogenous DAMPS signal Jun amino-terminal 
kinases JNK-AP1 and NF-κB through TLRs (11).   
The second step is post-transcriptional and activates the assembly of the 
inflammasome (49).  NLRP3 inflammasome assembly involves the protein thioredoxin 
interacting protein (TXNIP).  Upon stimulation from substances such as uric acid 
crystals, TXNIP dissociates from thioredoxin (TRX) and binds to NLRP3 inflammasome 
allowing for activation (55).  TXNIP participates in the glucose-induced secretion of IL-
1β in β-cells (55).  AMP-activated protein kinase (AMPK) phosphorylates TXNIP, which 
leads to a proteasome-dependent degradation of TXNIP, and down-regulates the binding 
of TXNIP to NLRP3 inflammasome (56).  AMPK has been identified as a potent 
regulator of the pro-inflammatory inducible nitric-oxide synthase (iNOS), and could be a 
target for alleviating chronic inflammation in conditions such as obesity-induced diabetes 
(57).  The exact mechanism of NLRP3 inflammasome activation is highly debated, and 
may involve multiple processes, including lysosomal damage and frustrated 
phagocytosis, intracellular K
+
 efflux, ROS production, Ca
2+
 signaling, deubiquitination, 
and microRNA signaling. 
 
8 
 
A. Lysosomal Damage 
One model that has been proposed is lysosome destabilization and frustrated 
phagocytosis (58).  Crystalline and particle activators of the inflammasome seem to 
induce lysosome destabilization and cathepsin B secretion which triggers NLRP3 
inflammasome (27).  However, this model does not apply to the activators nigericin or 
R837 (27).  Permeablization of the lysosome leads to deterioration of mitochondrial 
function and increases NLRP3 inflammasome activation (59).  Heid et al. (59) also 
proposed that activation of the NLRP3 inflammasome involves damage to the 
mitochondria and lysosome which leads to inflammasome activation and cellular 
damage.  Many other researchers have identified reactive oxygen species (ROS) as 
participating in inflammasome activation, and the induction of mitochondrial and 
lysosomal damage may link these mechanisms. 
 
B. K
+
 Efflux 
Researchers implicate K
+
 efflux in NLRP3 inflammasome activation (29).  
Franchi et al. (29) found that low intracellular K
+
 is necessary for NLRP3 activation by S. 
aureus and E. coli.  NLRP3 activation by silica was dependent on intracellular K
+
 efflux 
as well as ROS production (25).  Intracellular K
+
 efflux is a factor in the activation of the 
inflammasome through extracellular ATP, MSU, and Nigericin (38).  Petrilli et al. (60) 
and Shimada et al. (30) state that K
+
 efflux is a unifying theme among NLRP3 
inflammasome activators.  However, Jin et al. (27) note that although intracellular K
+
 
efflux is common among many NLRP3 inflammasome activators, it may not be sufficient 
for activation.  Extracellular K
+
 decreases IL-1β secretion and NLRP3 inflammasome 
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activation in bone marrow-derived macrophages (BMDM) (59) and diminished 
mitochondrial damage in BMDM (28).  Likewise, providing extracellular K
+
 prevented 
K
+
 efflux and inhibited caspase-1 activation in human monocytes (THP1 cells) (30).  On 
the other hand, low intracellular K
+
 triggers P2X purinoceptor 7 (P2X7R) to activate 
caspase-1 in macrophages (29).  P2X7R binds with the NLRP3 inflammasome during 
activation (61).  As discussed later, mitochondrial damage and ROS production play a 
role in inflammasome activation, and this could link these two common activation 
mechanisms.   
 
C. ER Stress 
The ER is considered a “nutrient-sensing” organelle (62).  The metabolic stress of 
obesity can alter cell metabolism by increasing ER stress, mitochondrial dysfunction, 
which leads to ROS production and oxidative stress (62).  The ER is highly sensitive to 
glucose metabolism and energy levels.  ER stress may impair hepatic gluconeogenesis in 
obesity and type 2 diabetes (T2DM) (62). Hotamisligil et al. (62) postulate that ER stress 
is increased in metabolically active tissues during obesity.  C-Jun N-terminal kinase-
activator protein-1 (JNK-AP1) and NF-κB are two inflammatory pathways that are 
implicated in the development of insulin resistance, inducing oxidative and ER stress, and 
are signaled through saturated fatty acids (SFA) and are thus key to the relationship 
between obesity, insulin resistance, and inflammation (11).  During ER stress, unfolded 
proteins accumulate, leading to the unfolded protein response (UPR) (62).  The purpose 
is to decrease protein synthesis and increase protein degradation to relieve the stress of 
accumulated unfolded proteins (62).  If ER stress is not resolved, it leads to apoptosis 
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(62).  Cox et al. (63) demonstrated that ER stress leads to the unfolded protein response 
(UPR), which activates the transmembrane sensor inositol-requiring enzyme 1 (IRE-1α) 
to resolve the stress.  Protein kinase R-like endoplasmic reticulum kinase (PERK) and 
IRE1-α, two kinases, and activating transcription factor 6 (ATF6) detect unfolded protein 
and activate UPR pathways (64).  IRE1-α and PERK become engaged in response to ER 
stress, and ATF6 is diminished and signals to the Golgi apparatus (62).  When IRE1 is 
engaged, it binds to mRNA to prevent protein translation (62).  In addition to IRE1 
signaling, ER stress also leads PERK to induce NF-κB activation, a transcription factor 
that increases pro-inflammatory gene expression (62).   
ER stress occurs in NLRP3 inflammasome activation/assembly.  Inhibiting ER 
stress through tauroursodeoxycholic acid (TUDCA) protected the livers of obese mice 
from LPS-induced injury, apoptosis, and inflammasome priming through decreasing 
IRE1-α and PERK activation (46).  Decreasing ER stress through TUDCA prevented 
NLRP3 inflammasome activation in kidney epithelial cells (65).  Angiotensin-II 
stimulation in human kidney-2 (HK-2) cells leads to ER stress which activates the 
NLRP3 inflammasome and increases caspase-1 activation and IL-1β and IL-18 secretion 
(36).  Lerner et al. (64) found that ER stress acts post-transcriptionally to increase IL-1β b 
secretion.  Contrarily, Kim et al. (66) found that ER stress both increased NF-κB 
activation (which increased pro-IL-1β expression) and induced IL-1β secretion in 
BMDM.   
Insulin resistance can lead to ER stress and is related to PERK and JNK signaling 
(62).  In pancreatic β-cells, PERK and IRE1-α signal TXNIP, ultimately inducing NLRP3 
inflammasome activation and IL-1β secretion (39).  ER stress signals the inflammasome 
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through dissociating dissociates TXNIP from TRX (67).  Lerner et al. (64) found that 
UPR induces TXNIP through IRE1-α.  IRE1-α induces TXNIP activity through the 
microRNA miR-17, and TXNIP activates NLRP3 inflammasome and increases IL-1β 
secretion through increased levels of ROS (64).  Lerner et al. (64) demonstrated the 
TXNIP activation of NLRP3 inflammasome mediated β-cell death due to ER stress, 
leading to diabetes in rodents.  On the other hand, Lebeaupin et al. (46) showed that 
PERK and IRE1-α activate C/EBP homologous protein (CHOP), which in turn, acts on 
the NLRP3 inflammasome and hepatic apoptosis.  In the hepatocytes, TXNIP does not 
appear to play a role in ER-stress induced inflammasome activation, though the IRE1-α -
PERK-CHOP axis is pivotal to ER-mediated inflammasome damage in the liver (46).   
Zhao et al. (67) connected ER stress to ROS since the increase in protein folding 
also increases ROS production in the ER.  ROS production and TXNIP was essential to 
NLRP3 assembly and activation in macrophages (66).  Decreasing ER stress through 
increased AMPK activity and decreased IRE1-α and PERK phosphorylation decreased 
intracellular ROS and inhibited NLRP3 inflammasome activation (68).  Lowering IRE1-α 
phosphorylation ameliorates ER stress as well as ROS production in response to high 
glucose in endothelial cells (69).  Menu et al. (70) found that both K
+
 efflux and ROS 
production are necessary when the NLRP3 inflammasome is activated through ER stress.  
Blocking K
+
 efflux and ROS production in human macrophages inhibited ER-stress 
induced IL-1β secretion (70).  The researchers also proposed that neither phagocytosis 
nor UPR was required for NLPR3 activation.  This demonstrates that the role of UPR and 
ER stress may be specific to cell type (58). 
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D. ROS 
Many researchers suggest that many NLRP3 inflammasome activators lead to 
ROS production (27).  For example, extracellular ATP increases ROS production and 
activates the NLRP3 inflammasome in macrophages (71).  Some argue that ROS is 
necessary for NLRP3 inflammasome activation because ROS inhibitors inhibit NLRP3 
inflammasome activation (24).  Indeed, inhibiting ROS production inhibits both NLRP3 
inflammasome expression and activation (25,72), and IL-1β production (59).  Inhibiting 
mitochondrial ROS through N-acetyl-L-cysteine (NAC) lowered expression of NLRP3 
and IL-1β and IL-18 (73).  Scavenging mitochondrial ROS through molecular hydrogen, 
which targets the mitochondria and scavenges ●OH, inhibited NLRP inflammasome in 
mouse macrophages (74).  Li et al. (40) demonstrated that during acute exercise, 
increased oxidative phosphorylation increased ROS production and led to NLRP3 
inflammasome activation and mitophagy in the myocardiam.  Bauernfeind et al. (50) 
found that inhibiting ROS blocked the priming step of NLRP3, not the activating signal.  
Changes in the redox balance in cells towards a more reduced state during chronic 
disease may activate the innate immune response to activate the NLRP3 inflammasome 
and produce IL-1β (75).  The NLRP3 inflammasome is particularly sensitive to changes 
in redox conditions because of a highly conserved disulfide bond in the PYD domain and 
the nucleotide-binding site domain (76).  During the resting state, monocytes have a 
balanced redox state, but TLR signaling leads to an oxidative hit which increases ROS 
production that activates NLRP3 inflammasome and produces IL-1β (75).  Carta et al. 
(75) proposed that the difference in redox states between THP-1, monocytes, and raw 
macrophages accounts for differing IL-1β responses to pro-oxidants and antioxidants.  
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Indeed, ROS oxidize TRX and release TXNIP, which binds to the NLRP3 inflammasome 
(55).  
The source of the ROS that activates the NLRP3 inflammasome is not yet clear.  
It was first hypothesized that NADPH oxidases were the source of the ROS that activate 
NLRP3 inflammasome (24).  Liao et al. (77) found that ROS production through 
NADPH oxidase was required for priming and activation stages of NLRP3 
inflammasome activation in mouse macrophages.  LPS increased NF-κB activation 
through NADPH oxidase ROS, and ATP induced NLRP3 inflammasome assembly 
through NADPH oxidase in macrophages (77).  Endogenous ROS production that was 
NADPH oxidase-dependent in mouse glomeruli activates the NLRP3 inflammasome and 
perpetuates hyperhomocysteinemia (78).  Similarly, NADPH oxidase was found to play a 
role in NLRP3 inflammasome activation in mouse podocytes and in the recruitment of 
macrophages and T-cells, as well as the development of hyperhomocysteinemia (79).  
Artlett et al. (37) note that ROS production from NADPH oxidase is involved in the 
chronic activation of NLRP3 inflammasome in fibrotic diseases.  Despite the evidence 
implicating NADPH oxidase in NLRP3 inflammasome activation, both mouse and 
human models lacking NADPH oxidase retained NLRP3 inflammasome function (80-
84). 
Mitochondrial dysfunction appears to be involved in ROS-mediated NLRP3 
inflammasome activation as well.  NLRP3 inflammasome activation impairs 
mitochondrial function (59).  Inhibiting mitochondrial ROS lowers IL-1β secretion (59). 
Inducing ROS production and mitochondrial stress activates the NLRP3 inflammasome 
and causes cell pyropotsis and apoptosis in HaCaT cells (85).  Kim et al. (66) found that a 
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reduction in mitochondrial membrane potential induced ROS production that activated 
NLRP3 inflammasome.  Mitochondrial ROS production increases NLRP3 inflammasome 
activity and IL-1β production in macrophages (86).  Scavenging mitochondrial ROS 
through molecular hydrogen inhibited NLRP inflammasome in mouse macrophages (74).  
Down-regulation of the NLRP3 inflammasome protected the hippocampus from 
ischemic-related damage and preserved mitochondrial function from glutamate 
neurotoxin (68). 
The decrease in mitochondrial ROS decreased NLRP3 inflammasome activation 
through ATP stimulation (87).  Oh et al. (87) found that inhibiting mitochondrial ROS 
production in macrophages did not affect transcriptional levels of NLRP3 or pro-IL-1β, 
but diminished NLRP3 inflammasome activation.  At rest, the NLRP3 inflammasome is 
mostly located at the mitochondria-associated ER membrane (MAM), and upon 
stimulation, ASC relocates to the MAM.  This relocation is dependent on the presence of 
NLRP3 (88).  Additionally, ROS production caused TXNIP to relocate to the 
mitochondria (88).  The mitochondrial damage that resulted in ROS production was due 
to inhibition of autophagy and mitophagy (88).  This was corroborated by Nakahira et al. 
(89), who demonstrated that depleting autophagic proteins impairs mitochondrial 
integrity and increases ROS production, which activates the NLRP3 inflammasome.  
Sorbara et al. (90) suggest that NLRP3 inflammasomes are activated by mitochondrial 
ROS, and autophagy clears dysfunctional mitochondria leading to inhibition of the 
NLRP3 inflammasome. 
Nakahira et al. (91) also found that NLRP3 inflammasome activation results in 
release of mitochondrial DNA (mtDNA).  Molecular hydrogen inhibits mtDNA priming 
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of NLRP3 inflammasome (74).  Additionally, blocking NLRP3 inflammasome activation 
simultaneously decreases mtDNA release (72).  Activation through ATP induces mtDNA 
release to the cytosol, which binds to and activates the NLRP3 inflammasome (28).  
Bauernfeind et al. (50) hypothesize that the differential requirements for ROS production 
in inflammasome activation are due to the fact that cells express varying levels of NLRP3 
inflammasome, and thus may or may not need to be primed.  Menu et al. (70) found that 
dampening mitochondrial activity inhibited ER-stress induced NLRP3 inflammasome 
activation, but not when human macrophages were stimulated with MSU.  This indicates 
that the involvement of mitochondrial ROS may depend on the stimulant.   
In addition to NADPH oxidase and mitochondrial dysfunction, there are other 
sources of ROS, including cyclooxygenases (COXs), cytochrome P450s, lipoxygenases 
(LOXs), and xanthine/xanthine oxidase (X/XO) (58).  These sources of ROS have the 
potential to affect the inflammasome, but their role has yet to be fully elucidated.  
Inhibiting ROS production diminished NLRP3 activation through the mitigation of 
oxidized LDL (oxLDL), but the authors suggested that K
+
 efflux and lysosome 
destabilization may play a role as well (92).  Wu et al. (91) suggested that ROS 
production due to palmitic acid addition links ER stress with TXNIP induction and 
NLRP3 inflammasome activation. 
 
E. Intracellular Ca
2+
 
Ca
2+
 signaling appears to be involved with NLRP3 inflammasome activation as 
well.  Ca
2+
 increases during cell stress, which lowers cAMP, ultimately activating the 
inflammasome (93).  Artlett et al. (37) suggest modulating calcium homeostasis may 
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regulate inflammasome activation.  Ca
2+
 plays a role in inflammasome activation by 
ATP, nigericin, MSU, and alum (94).  Murakami et al. (94) found that inhibiting 
mobilization of Ca
2+
 stores prevented ATP-induced NLRP3 inflammasome activation.  
During ATP-stimulated inflammasome activation, Ca
2+
 is released from the ER leading 
to an influx of extracellular Ca
2+
 (94).  The transcription factor CCAAT-enhancer-
binding protein (C/EPB) can release Ca
2+
 from the ER and lead to NLRP3 inflammasome 
activation, which shows how ER stress may activate the inflammasome (94).  
Phaygolysosomal rupture may lead to Ca
2+
 influx because the lysosomotropic peptide 
Leu-Leu-OMe induces both phagolysosomal rupture and the NLRP3 inflammasome, and 
lysosome rupture releases stored Ca
2+
 (94).  Flux of Ca
2+
 also leads to mitochondrial 
damage (94).  Murakami et al. (94) demonstrate that K
+
 efflux may lead to Ca
2+
 influx, 
and sustained Ca
2+
 influx can damage the mitochondria, which could lead to 
inflammasome activation.  Inhibiting Ca
2+
 signaling blocked mtROS production as well 
(94).  Chelating calcium protected from oxidative damage, and this demonstrated that 
calcium flux leads to ROS production (95).  However, Ca
2+ 
influx is not sufficient for 
NLRP3 inflammasome activation (94). 
 
F. Additional Mechanisms 
Deubiquitination and microRNAs have also been proposed as other mechanisms 
of NLRP3 inflammasome activation (58).  NLRP3 inflammasome activation through 
deubiquitination is due to a basal level of NLRP3 that is ubiquitinated but can be 
deubiquitinated upon LPS or ATP treatment, which signal activation through TLRs and 
mtROS in mouse macrophages (96).  MicroRNAs (miR) may also impact NLRP3 
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inflammasome activation.  MiR-223 has been specifically identified as a potential 
regulator of the NLRP3 inflammasome (97,98). High levels of miR-223 lowers NLRP3 
protein levels and decreases IL-1β secretion, and infecting B cells with exosomes 
containing miR-223 inhibited NLRP3 inflammasome activation (98).  
 
Figure 2. A summary of NLRP3 inflammasome activation. NLRP3 activation requires 
two signals—a priming signal through NF-κB, and an activating signal. The second 
signal involves ROS production, K
+
 efflux, lysosomal degradation, Ca
2+
 signaling, and 
ER stress. (99) 
1.4. Metabolic Implications of NLRP3 Inflammasome Activation 
A. The Relevance of IL-1β Production in NLRP3 Inflammasome 
IL-1β is a pro-inflammatory cytokine that is linked with many inflammatory 
conditions.  IL-1β is implicated in cognitive decline (100).  IL-1β is also implicated along 
with cyclooxygenase-1-mediated prostaglandins in the development of acute cognitive 
deficits (101).  Importantly, it may lead to the development of insulin resistance.  A study 
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based on the European Prospective Investigation into Cancer and Nutrition (EPIC)-
Potsdam study, which included 27,548 individuals found that plasma levels of IL-1β and 
IL-6 were predictive of the risk of T2DM  (102).  In obese patients, IL-1β and IL-1Ra are 
up-regulated in adipose, demonstrating its integral role in the pathogenesis of obesity-
related diseases (103).  In addition, higher levels of IL-1β and IL-1Ra affected the 
hypothalamus and adipocyte metabolism resulting in weight gain (103). 
High glucose concentration in pancreatic β-cells leads to IL-1β production and 
NF-κB activation, which led to β-cell death (104).  In β-cells, IL-1β leads to iNOS gene 
expression, which produces nitric oxide (NO), ultimately contributing to β-cell death and 
insulin resistance (105).  NF-κB increases gene expression of iNOS, which, together with 
IL-1β, mediates β-cell death (106).  IL-1β increased NF-κB expression, and NF-κB 
activation induced iNOS and monocyte chemoattractant protein-1 (MCP-1) (107).  
Khodabandehloo et al. (108) demonstrated that IL-1β and TNF-α activate iNOS which 
leads to Akt inactivation and subsequent impairment of insulin sensitivity.  IL-1β is also 
related to increased insulin sensitivity since IL-1β induces ER stress through Ca2+ flux, 
which leads to β-cell death (109).  In C57BL/6 mice treated with IL-1β antibodies for 13 
weeks demonstrated improved hemoglobin A1c (HbA1c), decreased insulin levels, and 
improved blood glucose (110).  Anakinra, a well-documented IL-1Ra antagonist, lowers 
HbA1c and fasting glucose in type 2 diabetic patients (111).  Though Larsen et al. (112) 
confirmed that IL-1Ra antagonists improved HbA1c and blood glucose levels, there was 
not a reciprocal improvement in insulin resistance.  IL-1β secreted from NLRP3 
inflammasome activation is thus an important target for improving outcomes of 
inflammatory conditions. 
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B. Obesity 
The NLRP3 inflammasome seems to be implicated in the pathophysiology of 
obesity.  Vandanmagsar et al. (17) found that the presence of NLRP3 is key for activation 
of inflammation in adipose and liver by obesity.  These researchers demonstrated that 
NLRP3 inflammasomes detect danger signals that lead to obesity-related inflammation 
and insulin resistance (17).  As body weight and adiposity increases, IL-1β and NLRP3 
mRNA levels increase in the visceral adipose tissue (VAT) (17).  Activation of the 
NLRP3 inflammasome in obesity leads to IL-1β and IL-18 production (17).  NLRP3 
ablation lowered interferon-γ (IFN-γ) and IL-18 levels and T cells in the adipose (17).   
Adipose tissue is particularly affected by NLRP3 inflammasome activation during 
obesity.  Both caspase-1 and NLRP3 inflammasome activation affect adipocyte formation 
(113).  During inflammation, anti-inflammatory macrophages can be polarized into a pro-
inflammatory state.  Deletion of the NLRP3 inflammasome mitigated adipose tissue 
macrophage (ATM) pro-inflammatory polarization in obesity (17).  NLRP3 knockout 
mice were protected from HFD induced obesity and demonstrated a lower adipocyte size 
(4).  NLRP3 knockout altered plasma leptin and resistin, affecting energy use, showing 
that NLRP3 inflammasomes modulates energy expenditure in overfeeding (4).  Mice 
deficient in caspase-1 fed a HFD expended greater energy compared to wild type mice 
fed a HFD, though total energy intake was the same (4).  The NLRP3 inflammasome can 
become activated during obesity, and helps perpetuate the detrimental effects of excess 
weight.  This activation of the inflammasome during obesity is related to metabolic 
dysfunction, such as cardiovascular disease, diabetes, and liver disease. 
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C. Cardiovascular Disease 
The inflammasome is implicated in the development of cardiovascular disease.  
Deletion of ASC improved parameters related to pulmonary hypertension in mice (114).  
Liu et al. (115) found that caspase-1 and NLRP3 inflammasome activity in the aorta was 
associated with vascular dysfunction in rats.  NLRP3 inflammasome expression is 
significantly higher in patients that are obese, or have dyslipidemia, diabetes, or 
hyperuricemia (116).  Additionally, coronary artery disease and coronary atherosclerosis 
were positively correlated with NLRP3 inflammasome expression in human 
subcutaneous adipose tissue (116).  Patients with acute coronary syndrome demonstrate 
higher levels of the NLRP3 inflammasome in peripheral blood monocytes (117). 
NLRP3 inflammasome activation is associated with impaired endothelial 
dysfunction, measured through the vasodilator response (5).  Cholesterol crystals, the 
result of hypercholesterolemia, activate the NLRP3 inflammasome and lead to the down-
stream production of HMGB1, which damages endothelial tissue (5).  HMGB1 is an 
early event during atherogenesis and endothelial dysfunction (5).  Fearon et al. (6) found 
that NLRP3 inflammasome and IL-1β production is implicated in the development of 
atherogenesis in both mice and humans.  The inflammasome is further implicated in 
atherosclerosis, since P2X7R and NLRP3 expression is increased in atherosclerotic 
plaque (118).  oxLDL further increases the expression of these pro-inflammatory proteins 
(118).  In addition, knockdown of P2X7R, which binds to NLRP3 inflammasomes during 
activation, protected mice from atherosclerosis development (118).  The role of the 
inflammasome in atherosclerosis is not fully delineated, but oxLDL may activate the 
21 
 
NLRP3 inflammasome, and the IL-1β secretion leads to foam cell formation (92).  
Within plaque, oxLDL activates NLRP3 inflammasome activation and IL-1β production, 
and this increased inflammation destabilizes the plaque (119).  Inflammasome activation 
may therefore worsen atherosclerosis in the context of hypercholesterolemia (58). 
Cholesterol crystals, elevated from hypercholesterolemia, activate the NLRP3 
inflammasome in coronary arteries (5). Activation of the NLRP3 inflammasome from 
cholesterol crystals may be mediated through superoxide production (5).  Duewell et al. 
(120) also found that cholesterol cholesterols activated the NLRP3 inflammasome.  In 
atherosclerosis-prone Apo-E deficient mice, cholesterol crystals induced IL-1β release, 
but this was eliminated in NLRP3- and ASC- deficient macrophages (120).  Duewell et 
al. (120) propose that oxLDL could provide the priming and the activating signal, 
releasing IL-1β.  These researchers demonstrate that NLRP3 inflammasome activation in 
bone marrow derived cells promoted atherosclerosis development in mice (120). 
 
D. Diabetes 
Metabolic inflammation during obesity seems to be critical to developing insulin 
resistance, and is a unifying factor in processes including ER stress, hypoxia, and 
lipotoxicity (11).  During obesity, increased inflammation is seen in tissues such as the 
liver and pancreatic islets, which can induce metabolic dysfunction (11).  NLRP3 
inflammasome activation impairs glucose homeostasis and insulin signaling (121).  
Vandanmasgar et al. (17) demonstrated that the NLRP3 inflammasome is critical for the 
development of peripheral insulin resistance and T2DM through the action of IL-1β.  
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NLRP3 inflammasome impairs insulin sensitivity (113), and NLRP3 ablation improved 
insulin signaling (17).   
The NLRP3 inflammasome is critical for the development of T2DM from islet 
amyloid polypeptide (IAPP) activation, which forms in the pancreas during T2DM (122).  
In addition, activation of the JNK-AP1 and NF-κB pathways interferes with insulin 
sensitivity by increasing inflammatory cytokines and decreased GLUT4 expression (11).  
NLRP3 deficient mice had lower glucose levels and improved insulin sensitivity, which 
was linked to mitogen-activated protein kinases (MAPK) pathway activation in visceral 
fat (17).  SFA priming of the inflammasome links HFD-induced obesity to insulin 
resistance and inflammation through altering cytokine production in dendritic cells (123).  
This could be due to the production of cytokines, since IL-1β impairs insulin signaling in 
vitro (121).  In obese type 2 diabetic patients, decreased NLRP3 expression in adipose 
tissue is associated with lowered inflammation and improved insulin signaling (17).  
NLRP3 knockout protected mice from obesity-induced insulin resistance (4).  In mice fed 
a HFD for 16 weeks, the deletion of TLR4 signaling in hematopoietic cells protected 
from fasting hyperinsulinemia, which displayed improved insulin sensitivity despite 
being obese (10).  This demonstrates the critical role of TLR4 signaling in the 
development of HFD-induced insulin resistance (10).  Taken together, this evidence 
shows that the inflammasome is important for linking obesity, inflammation, and T2DM. 
   
E. Liver Disease 
Liver damage involves NLRP3 inflammasome activation.  The NLRP3 
inflammasome can be activated in hepatocytes (46), and it is implicated in alcohol-
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induced liver inflammation, liver damage, and steatosis (34). Alcohol damage to 
hepatocytes induces the release of ATP and soluble uric acid which leads to the secretion 
of IL-1β from liver immune cells (34).  The NLRP3 inflammasome mediates liver 
damage due to acute alcohol binge-drinking (34).  Additionally, NLRP3 inflammasome 
derived IL-1β and IL-18 leads to hepatotoxicity induced by APAP (acetaminophen) 
(124).  The NLRP3 inflammasome has additionally been linked with hepatic steatosis.  
NLRP3 inflammasome expression is increased in the livers of patients with NASH and 
chronic hepatitis C virus (7).  In contrast, ablation of NLRP3 improves hepatic steatosis 
(17).  Similarly, NLRP3 knockout in mice led to lower hepatic triglyceride content (4).  
The NLRP3 inflammasome is further implicated in the development in liver disease, 
because it is required for liver fibrosis development (8).  In the liver, the NLRP3 
inflammasome plays a role in inflammation and the development of many liver diseases. 
 
F. Renal Disease 
The NLRP3 inflammasome also plays a role in kidney disease.  It is activated in 
the kidneys of diabetic patients and is involved in proteinuria (65).  The NLRP3 
inflammasome is also involved in albuminuria (73).  Nondiabetic patients with acute and 
chronic kidney disease (i.e. IgA nephropathy, minimal change disease, membranous 
glomerulopathy, lupus nephritis, secondary focal segmental glomerulosclerosis (FSGS), 
and hypertension/vascular nephrosclerosis) have increased gene expression of NLRP3 
that correlates to the level of kidney function (125).  In addition, inflammasome 
activation may mediate tubulointerstitial fibrosis in the renal tubule (65).  The NLRP3 
inflammasome plays a role in renal dysfunction and the influx of neutrophils during renal 
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ischemic acute tubular necrosis (9).  Caspase-1 activation may trigger pyroptosis, which 
may play a role in the damage from glomerular sclerosis and end-stage renal disease 
(ESRD) (58).  NLRP3 inflammasome activation is implicated in hyperhomocysteinemia 
(78).  Xia et al. (126) found that high levels of plasma homocysteine activates the NLRP3 
inflammasome in mouse glomeruli.  NLRP3 ablation ameliorated 
hyperhomocysteinemia-induced glomerular and podocyte injury (126).  Nlrp3 gene 
deletion protected from unilateral ureteral obstruction induced inflammation, fibrosis, and 
tubular injury (125).  NLRP3 inflammasome activation in the kidney can promote 
inflammatory-related damage and kidney disease. 
 
1.5 Dietary Regulators of the NLRP3 Inflammasome 
A. Fatty Acids as Regulators of the NLRP3 Inflammasome 
It is well known that diets high in saturated fats may be detrimental to health.  
Mice fed a long-term HFD (9 months) demonstrated NLRP3 activation in the liver (7).  
The relationship between the NLRP3 inflammasome and dietary fat may partially explain 
the metabolic consequences of dietary fat.  Snodgrass et al. (127) demonstrated that 
dietary fat affects IL-1β secretion from blood monocytes.  Many have studied the effect 
of a HFD on adipocyte inflammation.  These studies reveal that 1) in mice, a HFD primed 
adipose tissue to produce IL-1β in vivo (128).  2) HFD in mice increases adiposity and 
caspase-1 activation in adipose (17).  HFD increases caspase-1 expression, as well as IL-
1β and IL-18 production levels (113).  This increase in cytokines may lead to metabolic 
dysfunction and an impaired glucose handling.  The development of insulin resistance 
due to a HFD is well-characterized in adipose tissue.  Bone marrow-derived macrophages 
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(BMDCs) from HFD fed mice impaired insulin sensitivity in 3T3L1 adipocytes 
compared to BMDCs from chow-fed mice (123).  HFD primed BMDC cross-talk with 
adipocytes, resulting in diminished insulin signaling (123).  HFD increased expression of 
TLR4, caspase-1, and NLRP3 in BMDCs (123).  This may explain the higher reactivity 
of these HFD-derived BMDCs to LPS and ATP inflammasome activation (123).  It 
appears that a HFD increases inflammation through NLRP3 inflammasome activation, 
and the types of fatty acids in the diet differentially affect inflammasome activation. 
 
a. Saturated Fatty Acids 
High intake of SFAs is known to be detrimental to health, and this correlation 
holds true with NLRP3 inflammasome activation.  SFA priming of the NLRP3 
inflammasome impairs insulin sensitivity and leads to adipose inflammation in HFD-
induced obesity (123).  SFA-high diets signal NLRP3 inflammasome priming, leading to 
an inflammatory BMDC phenotype and impaired insulin signaling (123).  Palmitate 
activates the NLRP3 inflammasome in many cell types, including hepatocytes (7), human 
monocytes (127), endothelial cells (67), primary macrophages, monocytic leukemia cells, 
differentiated adipocytes (66), and hematopoietic cells (121).  In hepatocytes, palmitic 
acid activates the NLRP3 inflammasome and increases LPS sensitivity (7).  Palmitate 
activates NLRP3 inflammasome-related IL-1β production (129).  Inflammasome 
activation by palmitate in hepatocytes lead to danger signals that produce TNF-α 
production in liver mononuclear cells (7).  Treatment with palmitate leading to 
inflammasome activation and IL-1β secretion impaired insulin action in vitro (121). 
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There are several mechanisms by which palmitate increases NLRP3 
inflammasome activation.  Palmitic acid activated NLRP3 inflammasome in raw 264.7 
macrophages through TLR2 and TLR4 signaling that activated JNK and IκB kinase 
(IKK) cascades (130).  Snodgrass et al. (127) found that palmitic acid increases NLRP3 
inflammasome through TLR2 signaling, which increase IL-1β production in human 
monocytes.  TLR2 signaling induced NF-κB activation (127).  Monocytes express 
NLRP3 inflammasome and caspase-1 constitutively during the steady state, and 
stimulation with palmitate increased NLRP3 expression and IL-1β secretion (127).  In the 
endothelium, palmitic acid increases phosphorylation of IRE1-α and ROS production 
through ER stress and oxidative stress (67).  Palmitate induced IL-1β production in 
primary macrophages, monocytic leukemia cells, and differentiated adipocytes through 
induction of ER stress (66).  Wen et al. (121) propose that palmitate activates the NLRP3 
inflammasome through ROS production and K
+
 efflux which led to increased IL-1β and 
IL-18 secretion in hematopoietic cells and macrophages.  Palmitate inhibits AMPK, 
which lowered autophagy and increased mitochondrial ROS, leading to NLRP3 
inflammasome activation (121).  
Stearate also induces NLRP3 inflammasome in human monocytes/macrophages 
(131).  Both stearate and palmitate increased IL-1β production and NLRP3 activation in 
THP1 cells (131).  Nguyen et al. (130) found that arachidonic was the most potent FFA 
that activates the NLRP3 inflammasome, and myristic acid was unable to activate the 
inflammasome.  More controversial is ceramide’s role in inflammasome activation.  Diets 
high in saturated fat can increase ceramide synthesis levels (132).  Ceramide levels 
increase in adipose and plasma in C57BL/6J mice fed a HFD (133).  Ceramides activate 
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the NLRP3 inflammasome in BMDMs (17).  Adipose tissue macrophages (ATMs) 
stimulated with ceramides had increased caspase-1 activation, though this did not occur 
in NLRP3 knockout ATMs from mice (17).  Alterations in ceramide metabolism may 
contribute to metabolic syndrome (12).  Although Camell et al. (129) demonstrated that 
ceramide can activate the NLRP3 inflammasome through ROS production, mice lacking 
ceramide de novo synthesis in macrophages still demonstrated insulin resistance, leading 
to the conclusion that this pathway is not necessary for NLRP3 inflammasome activation.  
Ceramide synthesis may be dispensable during inflammation related to diet-induced 
obesity (129).  Taken together, these studies show that a high intake of SFAs can lead to 
NLRP3 inflammasome activation and the development of metabolic dysfunction due to 
the increase of inflammation. 
 
b. Unsaturated Fatty Acids 
In contrast to SFA, Wen et al. (121) found that the unsaturated fatty acid (UFA) 
oleate does not activate the NLRP3 inflammasome.  Csak et al. (7) demonstrated oleic 
acid and linoleic acid do not increase NLRP3 gene expression in hepatocytes and 
macrophages.  Linoleic acid, a polyunsaturated fatty acid (PUFA), does not prime the 
NLRP3 inflammasome and increase pro- IL-1β levels (123).  Moreover, the UFAs oleate 
and linoleate decreased IL-1β secretion in THP-1 cells stimulated by SFAs, and also 
Nigericin, alum, and MSU (131).  The addition of UFAs (oleate and linoleate) decreased 
IL-1β production, but not its transcription, whereas SFAs increased IκBα and P65 
phosphorylation (131).  Monounsaturated fatty acid (MUFA)-HFD impaired NLRP3 
inflammasome-mediated IL-1β production in pre-primed cells (128).  MUFA-HFD also 
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ameliorated insulin resistance and hyperinsulinemia in obese mice (128).  C57BL/6 mice 
on a diet supplemented with 3% menhaden fish oil and 7% safflower oil had decreased 
mRNA expression of caspase-1, NLRP3, and IL-1β compared to an isocaloric diet 
with10% safflower oil (134).  UFAs may inhibit NLPR3 inflammasome through 
induction of AMPK.  The MUFA oleic acid impaired IL-1β secretion in ATP-primed 
cells through up-regulation of AMPK (128).  MUFA-HFD in mice lowered pro- IL-1β 
levels, IL-1β production, increased AMPK activation, and ultimately improved insulin 
sensitivity compared to SFA-HFD in mice (128).  These studies support the widely 
accepted view that dietary UFAs are beneficial. 
 
c. Omega-3 Fatty Acids 
Omega-3 fatty acids are known to mitigate inflammation.  This anti-inflammatory 
power may be in part due to inhibition of NLRP3 inflammasome.  Docosahexaenoic acid 
(DHA), an omega-3 fatty acid, lowered pro-IL-1β expression induced by palmitic acid in 
human monocytes (127).  Yan et al. (135) found that omega-3 fatty acids, specifically 
DHA and eicosapentaenoic acid (EPA) inhibited NLRP3 inflammasome.  These 
researchers then investigated potential anti-inflammatory mechanisms that could be at 
work.  They found that enzyme modified enzymatic products, such as Protectin D1 
(PD1), Resolvin D1 (RvD1) and aspirin-triggered Resolvin D1 (ATRvD1), by 
lipoxygenases (AlOX5 and AlOX15) and aspirin-acetylated COX-2 were not involved 
(135).  Instead, they found G-protein coupled receptor (GPR) 40 and 120 were at work 
(135).  DHA and EPA signaled GPR40 and GPR120 (135).  This signaling was required 
for the inhibitory effect of omega-3 FA on inflammasome activation (135).  GPR40 and 
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GPR120 signaled overexpressed Arrestin, Beta 2 (ARRB2) to bind the LRR and NACHT 
portions of NLRP3 (135).  Williams-Bey et al. (136) also investigated the mechanism 
behind DHA’s and EPA’s inhibitory effect on the NLRP3 inflammasome.  These 
researchers found that DHA and EPA acted on the priming step of NLRP3 
inflammasome activation (136).  Omega-3 fatty acid treatment prevented nuclear 
translocation of NF-κB in THP-1 and mouse BMDMs (136).  Omega-3s increased 
intracellular calcium and increased the interaction between β-arrestins and free fatty acid 
receptor 4 (FFAR4), which ultimately down-regulated NF-κB and Jun kinase (136).  In 
addition, DHA increased autophagy in macrophages, which also decreased 
inflammasome activation because the NLRP3 inflammasome is degraded by the 
autophagosome (136). 
DHA supplementation lowered fasting glucose, improved insulin sensitivity and 
glucose sensitivity in an NLRP3-dependent manner in mice fed a HFD (135).  DHA also 
lowered production of pro-inflammatory cytokines, though this was not seen in NLRP3 
knockout mice (135).  This demonstrated that omega-3 fatty acids exhibit anti-
inflammatory effects that improve type 2 diabetic complications through GPR40 and 
GPR120 regulation of the NLRP3 inflammasome (135).  Reynolds et al. (137) notably 
found that in rats, male, but not female, offspring from HFD-fed mothers had increased 
expression of NLRP3, IL-1β, and TNF-α.  This trend was reversed with conjugated 
linoleic acid (CLA) supplementation (137).  Omega-3 fatty acids appear to be beneficial 
in inhibiting NLRP3 inflammasome activation. 
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B. Dietary Bioactive Compounds as Regulators of the NLRP3 inflammasome 
Polyphenols are dietary bioactive compounds that have many beneficial actions in 
the body.  Certain polyphenols—curcumin, quercetin, resveratrol, and epigallocatechin-3-
gallate (EGCG)—have been demonstrated to decrease NLRP3 inflammasome activation.  
Curcumin inhibits NLRP3 inflammasome activation and caspase-1 levels in macrophages 
treated with LPS (138).  Curcumin inhibited K
+
 efflux, which limited IL-1β production 
and HMGB-1 levels, which is a DAMP (138).  Quercetin, luteolin and epigallocatechin 
gallate are all flavonoids that increase AMPK phosphorylation (91).  Treatment with 
these compounds also lowered ROS production which inhibited TXNIP and NLRP3 
inflammasome activation when stimulated with palmitate (91).  These compounds 
inhibited mitochondrial cell apoptosis, mitigated inflammation in endothelial cells, and 
reduced cell death (91). 
Quercetin, a dietary flavonoid inhibits ROS production and hepatic oxidative 
stress in streptozotocin (STZ)-induced diabetic rats (139).  Wang et al. (139) found that 
50 and 100 mg/kg body wt quercetin (administrated through intragastric gavage) 
diminished TXNIP levels, as well as NLRP3 inflammasome activation and IL-1β 
secretion in the livers of STZ-injected diabetic rats and in HepG2 and BRL-3A cells 
treated with high glucose levels.  Wu et al. (91) demonstrated that in endothelial cells, 10 
μM quercetin increases AMPK phosphorylation and decreases ROS levels and TXNIP.  
This decrease in ROS and increase in AMPK phosphorylation led to lowered NRLP3 
inflammasome activation and lowered gene expression of IL-1β (91). 
Resveratrol is a polyphenol that is most well-known for its presence in wine.  
Supplementing mice fed a HFD with resveratrol improved blood glucose control and 
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triglyceride levels (140).  Resveratrol (8 mg/kg/d administered via osmotic pump) also 
ameliorated hepatic steatosis and lowered NLRP3 inflammasome levels (140).  Misawa 
et al. (141) investigated resveratrol’s inhibitory mechanism on the NLRP3 
inflammasome.  Acetylated α-tubulin facilitates the movement of mitochondria to the ER, 
which leads to the interaction between ASC (from the mitochondria) and the NLRP3 (on 
the ER), which activates the assembly of the NLRP3 inflammasome (141).  Acetylated α-
tubulin was decreased with 5 μM resveratrol treatment in mouse macrophages, 
consequently decreasing NLRP3 inflammasome activation (141). 
EGCG is a polyphenol found in green tea.  In lupus prone, New Zealand 
black/white (NZB/W) F1 mice, 120 mg/kg body wt EGCG inhibited ROS production and 
NF-κB activation in the kidney (142).  EGCG-treated mice demonstrated lower IL-1β and 
IL-18 levels, as well as NLRP3 activation in the liver (142).  EGCG lowered monocyte 
and macrophage infiltration to the liver and ameliorated prophylactic consequences of 
lupus nephritis in mice (142).  EGCG (10 μM) decreases NLRP3 inflammasome 
activation in endothelial cells through increased AMPK phosphorylation, and decreased 
TXNIP activity and ROS production (91).  These studies provide further proof of the 
benefit of dietary polyphenols. 
 
1.6 Conclusions 
Chronic inflammation mediates the detrimental consequences of auto-
inflammatory conditions and obesity-related conditions.  The NLRP3 inflammasome is a 
protein complex that is present in many types of cells and is activated by an extensive 
range of factors.  After up-regulation of pro-inflammatory genes, the assembly of the 
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inflammasome may involve such cellular processes as K
+
 efflux, lysosomal degradation, 
ER stress, and ROS production.  The NLRP3 inflammasome has clearly been shown to 
be active in inflammatory conditions and is integral to the pathophysiology of many 
conditions including metabolic dysfunction, T2DM, NASH, and renal disease.  NLRP3 
activation can lead to insulin resistance and the NLRP3 inflammasome links obesity with 
many of the negative consequences of excess weight.  Decreasing NLRP3 inflammasome 
expression and activation thus has many potential therapeutic applications. 
The NLRP3 inflammasome is modulated by a variety of dietary factors.  SFAs 
lead to NLRP3 inflammasome-related inflammation.  On the other hand, UFAs and 
omega-3 fatty acids decreased NLRP3 inflammasome activation.  Polyphenols, i.e. 
quercetin, curcumin, resveratrol, and EGCG, also attenuate inflammation by inhibiting 
inflammasome activation.  These studies provide further support to the USDA dietary 
guidelines, which recommend a diet low in saturated fat, and higher in MUFAs and 
PUFAs, with plentiful fruits and vegetables (143).  The Dietary Guidelines highlight the 
Mediterranean diet as an example of a healthful diet, characterized by high intakes of 
MUFAs and PUFAs, low intake of SFAs, and higher portions of whole grains, fruits and 
vegetables, and polyphenols (143).  There is still much to learn about the NLRP3 
inflammasome, and it is a promising method of ameliorating inflammation.  
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CHAPTER 2. EXPERIMENTS AND RESULTS 
 
2.1 Introduction 
The NRLP3 inflammasome has been implicated in a plethora of inflammatory 
diseases.  In particular, activation of the NLRP3 inflammasome appears to be linked to 
chronic low-grade inflammation during obesity, and the development of obesity-induced 
insulin resistance.  Therefore, our lab has investigated potential mediators of NLRP3 
inflammasome activation.  Specifically, our lab has examined the role of tocotrienols, 
which are known to be anti-inflammatory.  Macrophages or “big eaters,” are key immune 
cells intimately linked with inflammation in obesity and adipose inflammation as well.  
Though the NLRP3 inflammasome acts in many different cell types, macrophages are 
key factors in the innate immune response to overweight and obesity as well as a HFD.  
The outline of the mechanisms by which tocotrienols act will follow, as well as the role 
that macrophages play in chronic low-grade inflammation.  Also discussed is the 
potential of tocotrienols to inhibit NLRP3 inflammasome activation. 
 
A. Tocotrienols 
Vitamin E is divided into two classes—tocopherols with a saturated side chain, 
and tocotrienols, that contain 3 double bonds in the side chain (144).  α-, γ-, δ-, and β-
tocotrienols differ based on the functional group at the 5 or 7 position on the chromanol 
ring (144).  Tocotrienols are mainly found in vegetable oils including palm and rice bran 
oil, as well as oats, rye, barley, and other cereal grains (145).  Palm oil is a common 
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source for tocotrienol supplements (146).  The vitamin E content in palm oil is 30% 
tocopherols and 70% tocotrienols (146). 
 
Figure 3: Tocotrienol content in various food sources (147) 
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Figure 4. Tocotrienol structure (148) 
a. Properties 
Our lab has investigated tocotrienols for their anti-inflammatory effect.  
Tocotrienols are forms of vitamin E that exhibit antioxidant, anti-proliferative, anti-
survival, pro-apoptotic, antiangiogenic, and anti-inflammatory activities (147).  
Tocotrienols are well-known antioxidants (149-159).  Tocotrienols are more powerful 
antioxidants than tocopherols.  Alpha-tocotrienol (aT3) is 40~60-fold more potent at 
mitigating lipid peroxidation in rat liver microsomal membranes and 6.5-fold more potent 
(aT3) 
 
(gT3) 
 
(dT3) 
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at decreasing oxidative damage compared to alpha-tocopherol (aTP) (150).  aT3 has 
greater antioxidant ability to decrease in vivo oxidative stress, possibly due to its 
increased effectiveness as an antioxidant in membranes (151).  It is believed that the 
unsaturated side chain allows the tocotrienols to interact with lipid radicals more freely in 
the cell membrane (151).  The well-documented antioxidant property of tocotrienols is 
induced through enzymes including superoxide dismutase (160,161).  Vitamin E also 
induces NADPH: quinone oxidoreductase and glutathione peroxidase (162).  The anti-
oxidant properties of tocotrienols come in part from their ability to decrease TNF (163-
165), IL-1β (166), IL-6 (167), and IL-8 levels (168).  Tocotrienols ameliorate oxidative 
stress, chronic inflammation, and modulated apoptosis (165).   
Tocotrienols are able to regulate cholesterol synthesis.  Tocotrienols directly bind 
to 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase and decrease 
cholesterol synthesis (147).  In rats, supplementing tocotrienols (as the tocotrienol rich 
fraction (TRF) from palm oil) lowered LDL-cholesterol and total cholesterol due to the 
inhibitory effects on HMG-CoA reductase (169).  Qureshi et al. (170) conducted an 8-
week, double-blind crossover study with 25 human subjects with hypercholesterolemia.  
Tocotrienols (200 mg/day) lowered serum cholesterol by 31% within 4 weeks, and this 
decrease continued for 2 weeks, even after discontinuation of the supplement (170).  
Baliarsingh et al. (171) demonstrated that TRF supplement improved hyperlipidemia and 
atherogenesis in 19 patients with T2DM.  TRF supplement for 60 days resulted in a 
reduction in serum total lipids, total cholesterol (TC), and LDL-C, although there was no 
improvement in glycemia in these subjects (171).  However, not all studies found a 
cardioprotective effect of tocotrienol supplements (172).  Some have proposed that the 
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differing outcomes could be due to the presence or absence of aTP in the supplements 
administered to the subjects (173).  In chickens, aTP was shown to interfere the 
cholesterol-lowering effect of tocotrienols (174). 
Another mechanism of tocotrienols work is inhibition of NF-κB activation.  A 
combination of tocotrienols have been shown to inhibit NF-κB activation.  Tocotrienols 
(α, β, γ) administration in pups with ethanol-induced impaired cognitive function 
decreased NF-κB p56 expression in the nuclear fraction (175).  In mouse peritoneal 
macrophages, TRF was more powerful than aTP on inhibiting NF-κB expression, as well 
as decreasing LPS-induced nitric oxide, and TNF-α, IFN-γ, IL-1β, and IL-6 production 
(176).  Similarly, TRF protected THP-1 cells from LPS-induced cell death through 
diminishing NF-κB expression alongside a decrease in TNF-α, IL-4, and IL-8 production 
(177).  This inhibitory effect in immune cells was found when Theriault et al. (178) 
demonstrated that aT3 inhibited NF-κB activation by 30% in monocytes.  In 
lymphocytes, gamma tocotrienol (gT3) pretreatment inhibited NF-κB activation and the 
production of the pro-inflammatory cytokine IFN-γ (179).  Tocotrienols appear to be 
more effective than tocopherols at inhibiting NF-κB priming.  Kuhad et al. (165) 
demonstrated that tocotrienol administration in STZ-injected mice prevented ROS-
induced NF-κB p65 subunit expression in the nuclear fraction of STZ-treated rat kidneys.  
In their study, tocotrienols were more effective than aTP at decreasing NF-κB expression 
and inhibiting caspase-3 (165).   
This alteration in NF-κB activation contributes to the anti-cancer and anti-
inflammatory properties of tocotrienols.  Tocotrienols inhibiting NF-κB expression in 
two human breast cancer cell lines (180).  Tocotrienols have also been studied for cancer 
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protection, and it has anti-cancer effects in many different tumor cell types (147).  
Tocotrienols are anti-proliferative in breast, colon, liver, lung, pancreas, prostate, skin, 
and stomach tumor cells (147).  This antiproliferative effect of tocotrienols is in part due 
to its inhibition of MAPK and ERK (181) and JNK (182).  Tocotrienols may be potent in 
reducing cancer due to its angiogenesis suppressive property (183,184). 
Tocotrienols are also beneficial for mitigating adverse effects of diabetes.  
Siddiqui et al. (185) demonstrated that TRF supplementation in STZ-injected diabetic rats 
protected against diabetic nephropathy.  TRF supplementation improved glycemia, 
lowered HbA1c, decreased oxidative stress, lowered lipid peroxidation, and improved 
serum triglycerides (185,186).  A placebo-controlled, randomized double-blind study 
with 44 type 2 diabetic patients examined the effects of a 200 mg/d tocotrienol 
supplement combined with noninsulin hypoglycemic medications (187).  These 
researchers found that tocotrienols improve fasting blood glucose, through there was no 
improvement in HOMA-IR (187).  Oral tocotrienol supplements in STZ-induced diabetic 
rats improved renal function, prevented lipid peroxidation and lowered TNF-α levels 
(165).  The researchers proposed that these improvements were partly due to the action of 
tocotrienols of NF-κB signaling (165).  Another study by Fang et al. (188) found that 
tocotrienol supplements reduced blood glucose levels in animal and patient models, 
potentially by acting on peroxisome proliferator-activated receptor (PPAR) modulators. 
Tocotrienols prevented nicotine-induced bone loss (189) and improve normal 
bone structure and calcification (190,191).  The beneficial effect of tocotrienol on bone 
structure may be due to its antioxidant property (192).  Deng et al. (193) demonstrated 
that gT3 supplementation in C57BL/6 female mice treated and prevented osteoporosis, 
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and the gT3 accumulated in adipose, cardiac, and bone tissue.  Tocotrienols are 
gastroprotective and lower free radical damage, and stress-induced elevated gastric 
acidity levels (194).  Tocotrienols display a neuroprotective effect.  This could be due to 
a few potential mechanisms—the antioxidant abilities of tocotrienols may decrease 
oxidative stress in the brain; tocotrienols may lower hypercholesterolemia, a known risk 
factor of neurodegenerative disease; or tocotrienols may affect neuron cell death (173).  
Moreover, the tocotrienol levels needed to achieve this neuroprotective effect may be 
achievable through the diet (173).  It is evident that tocotrienols have widespread benefits 
in the body. 
 
b. Digestion, Absorption, and Supplements 
Tocotrienols are absorbed and transported in the body similarly to other fat-
soluble vitamins.  Tocotrienols are absorbed by Caco2 cells (colorectal adenocarcinoma 
cells) more readily than tocopherols due to the saturation of the side chains (195).  Caco2 
cells can be used as a cell model for lipoprotein metabolism (196).  Oral administration of 
delta tocotrienol (dT3) (100 mg/kg body wt) in female athymic nude mice led to a peak 
plasma concentration of 57±5 μmol/l, which occurred 2 h after administration (197).  
α­tocopherol transfer protein (ATTP), α­tocopherol associated protein (TAP), 
P-glycoprotein (P-gly) and human serum albumin (HSA) may provide docking complex 
for uptake of tocotrienols and tocopherols into chylomicrons (198).  Tocotrienols are 
cleared from the liver and plasma after 24 h (197).  Tocotrienols are distributed in the 
body via chylomicrons alongside triglycerides, and are absent from the plasma after 
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chylomicrons are cleared (199).  Carboxyethyl-hydroxychroman is the aT3 and gT3 
metabolite that is excreted in human urine (200). 
Oral tocotrienol supplementation in humans increases plasma tocotrienols to 
micromolar concentrations (201,202).  The plasma concentrations of a-, g-, and dT3, 
reached 4 h after a high fat meal supplemented with 77 mg aT3, 96 mg dT3, 3 mg gT3 
was 2.94 ± 0.68 µM, 3.16 ± 0.96 µM, and 1.41 ± 0.39 µM, respectively (202).  Uchida et 
al. (203) demonstrated that tocotrienol is deposited in the adipose tissue and these stores 
remain in the adipose without degradation for 4 weeks after 6 weeks of supplementation.  
Male Sprague Dawley (SD) rats on a diet of 6.4 mg vitamin E/100g wt for 3 weeks were 
given non-, low-T3 (0.8 mg tocotrienol/kg body wt/d), and high-tocotrienol (3.2 mg 
tocotrienol/kg body wt/d) diets (204).  The gT3 was significantly higher in the adipose 
tissue, and was increased from 1.1 to 10.2 nmol/g adipose tissue (204).  Patel et al. (205) 
found that tocotrienol oral supplements significantly increased tissue levels of tocotrienol 
in the skin blood, brain, adipose, cardiac muscle, and liver in human subjects over time.  
The levels of aT3 found in the brain in this study were found to be neuroprotective (205). 
Absorption of tocotrienols from intramuscular and intraperitoneal injections is 
negligible, but oral supplementation is more effective (206).  aT3 bioavailability is ~28%; 
gT3 and dT3 bioavailability is ~9% (206).  A tocotrienol intake of less than 0.20% of 
total dietary intake represents a safe amount in rats (207).  Nakamura et al. (208) found 
the no-observed-adverse-effect level (NOAEL) of tocotrienols to be 0.019% in the diet, 
or 120 mg/kg body wt/d in male rats, and 130 mg/kg body wt/d in female rats.  300 
mg/kg/d of dT3 or gT3 supplementation in male and female CD2F1 did not cause any 
adverse effects.  Palm TRF are certified by the US FDA as a Generally Recognized as 
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Safe (GRAS; GRN307, October 2009) nutrients, and tocotrienols are not considered a 
drug that has potential side effects.  However, there is not currently a recommended daily 
allowance (RDA) or tolerable upper limit (TUL) specifically for tocotrienols.  Self-
emulsifying formulas of tocotrienols have been tested in human subjects and were found 
to improve oral bioavailability through improving lipolysis (209).  Tocotrienol 
supplements would therefore be safe in the human diets. 
 
c. Delta Tocotrienol 
dT3 is unique among other tocotrienols due to its high availability in the annatto 
plant.  dT3 represents 90% of the tocotrienols found in the annatto plant, from which it is 
easily purified (210).  Despite its high bioavailability in the annatto, dT3 has not been 
extensively studied in connection to inflammation and T2DM.  As with the other 
tocotrienols, dT3 has anti-cancer and cardio-protective benefits. 
One well-characterized action of dT3 is an inhibitory action on the NF-κB, which 
leads to its anti-cancer and anti-inflammatory actions.  dT3 exhibited a growth-inhibitory 
effect and decreased NF-κB p65 in ED40515 cells (211).  dT3 inhibited cell growth and 
migration, increased apoptosis, and decreased NF-κB DNA binding ability in cancer cells 
(212).  In a pancreatic cancer model, dT3 was found to inhibit both pERK and NF-κB, 
which improved median survival (213).  Husain et al. (214) also demonstrated dT3’s 
ability to reduce tumor growth in human pancreatic cancer cells through inhibition of NF-
κB activity and expression.  STZ-injected diabetic rats supplemented with tocotrienols for 
10 weeks exhibited behavioral and biochemical improvements related to diabetes (164).  
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The researchers demonstrated that these improvements were due to a decrease in NF-κB 
p65 expression in the nuclear fraction of the rats’ brains (164). 
dT3 has been shown to have anti-cancer effects in pancreatic cancer (213-215), 
breast adenocarcinoma (216), non-small cell lung cancer (214,217,218), lymphoblastic 
leukemia (219), and melanoma (220).  Compared to aTP, dT3 demonstrated a greater 
ability to suppress angiogenesis and inhibit proliferation in human umbilical vein 
endothelial cells (HUVECs) (221).  In mice, an annatto-T3 supplement reduced breast 
cancer tumor mass, and lung metastases size through growth arrest and apoptosis, ROS 
production and gene expression associated with cancer development (210).  dT3 
effectively inhibited human colorectal adenocarcinoma growth through apoptosis and 
phosphorylation of protein kinase B (Akt) (222).  dT3 arrested cell growth in human 
bladder cancer cells (223).  dT3 treatment was found to lower ROS production and 
suppress melanogenesis through MAPK/ERK signaling (224).  dT3 also protects human 
cells from radiation-induced damage through down-regulation of microRNA-30c and IL-
1β expression (225).  Li et al. (225) demonstrated that this protective effect was through 
inhibited NF-κB signaling.  Singh et al. (226) investigated the dT3 radio-protective 
ability in CD2F1 mice, and found that it was due to dT3’s ability to induce granulocyte 
colony-stimulating factor (G-CSF).  Further, dT3 protects against radiation-induced 
gastrointestinal damage in CD2F1 mice (227).  These researchers also found that dT3 
reduced translocation of gut bacteria, protected intestinal cells, and decrease levels of IL-
1β and IL-6 (227). 
Rats fed a diet high in simple carbohydrates displayed obesity, insulin resistance, 
and hypertension (228).  However, dT3 supplementation improved cardiovascular 
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markers, hypertension, plasma lipids, blood glucose, and insulin signaling (228).  Though 
these rats displayed low to no levels of tocotrienol in the plasma, tocotrienols were 
deposited in adipose, liver, and heart tissue (228).  Supplementation with gT3 and dT3 in 
hypercholesterolemic mice reduced cholesterol and triglyceride synthesis and improved 
serum triglycerides (229).  Abdul-Majeed et al. (230) demonstrated that dT3 in SD rats is 
an effective treatment to prevent post-menopausal osteoporosis.  dT3 has been shown to 
be effective in ameliorating collagen-induced rheumatoid arthritis (231).  Though dT3 
has mostly been studied for its anticancer effects, it has potential beneficial effects in 
diabetes and cardiovascular diseases. 
 
d. Tocotrienols and the NLRP3 Inflammasome 
gT3 has been shown to mitigate inflammation associated with a HFD.  
Supplementing mice fed a HFD with gT3 ameliorated adipose inflammation, plasma 
levels of inflammatory cytokines, and IL-6 and IL-1β gene expression (232).  This was 
due to NF-κB inhibition.  Supplementing gT3 also improved insulin signaling, which 
demonstrates that gT3, through NFᴋB inhibition, decreases HFD-induced adipose 
inflammation and improves metabolic dysfunction (232).  Our lab has demonstrated that 
gT3 is anti-inflammatory in adipose tissue and is able to alter the macrophage profile in 
adipose.  gT3 supplementation in C57BL/6J mice fed a HFD decreased epididymal fat 
pad size (232).  Insulin resistance was improved in the gT3-supplemented mice as well 
(232).  Additionally, macrophage infiltration into the adipose, macrophage pro-
inflammatory polarization, and adipocyte inflammation were lowered with gT3 
supplementation (232).  This led to a subsequent study on the mechanisms leading to this 
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decrease in inflammation.  gT3 inhibited NLRP3 inflammasome activation in LPS- and 
nigericin- or palmitate-activated NLRP3 inflammasome in iJ774 macrophages (233).  In 
db/db mice, gT3 supplementation improved glycemia and β-cell mass (233).  gT3-
supplemented db/db mice displayed lower levels of NLRP3 inflammasome activation in 
peritoneal macrophages (233).  Thus, it was concluded that gT3 is able to inhibit the 
NLRP3 inflammasome. 
 
B. The Role of the Macrophage and the Immune System in Inflammation 
 The macrophage is commonly used as a model for NLRP3 inflammasome 
activation.  It is particularly relevant when studying the innate immune response and 
ensuing inflammation during metabolic dysfunction and obesity.  Macrophages are 
central to adipose inflammation and thus represent an ideal target to ameliorate chronic 
low-grade inflammation.  Danger signals during overweight and obesity activate the 
innate immune system and lead to sterile inflammation.  Diet-induced obesity leads to 
lower levels of CD4
+
 helper and regulatory T cells and infiltration of epididymal adipose 
tissue by CD8
+
 effector T cells, which recruit macrophages to the adipose (234).  
Infiltration of T cells and macrophages in visceral adipose tissue leads to chronic 
inflammation and contributes to the development of obesity-induced insulin resistance 
(235).   
The immune system is involved with the pathogenesis of obesity induced 
diseases.  In mice, a HFD induced infiltration of macrophages and dendritic cells, even 
before weight increased and insulin resistance declined, demonstrating that macrophage 
infiltration to the adipose is an early step in the development of obesity-induced insulin 
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resistance (130).  During obesity, macrophages are recruited to the adipose tissue and 
instigate inflammatory pathways that lead to low-grade inflammation in the adipose 
(236).  This is due to the production of MCP-1 by adipose in response to a HFD and leads 
to the  recruitment of macrophages to the adipose (11).  A HFD in NLRP3 knockout mice 
led to lower MCP-1 and consequently lower macrophage infiltration into adipose tissue 
(4).  Wild-type mice on the HFD had higher levels of macrophage infiltration, which 
leads to adipocyte inflammation and HFD-induced insulin resistance (4).  Macrophage 
cells comprise 10% of adipose tissue in lean mice and humans, which increases 
dramatically to 40% in obese humans and 50% in the adipose of leptin-deficient mice 
(236). 
 
Figure 5. The role of macrophages in inflammation. Weight gain during obesity leads 
cellular stress, which results in the recruitment of macrophages to adipose tissue.  These 
macrophages secrete pro-inflammatory cytokines and inflammatory factors, resulting in 
decreased insulin sensitivity. (237) 
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A HFD leading to elevated fatty acids activates macrophage NLRP3 
inflammasome, which was associated with impaired insulin signaling (121).  Obesity is 
marked by the polarization of anti-inflammatory M2 macrophages to the pro-
inflammatory M1 macrophage recruitment to adipose tissue (11).  These M1 
macrophages are connected to the development of insulin resistance and produce pro-
inflammatory cytokines (11).  Diet-induced obesity alters levels of CD4
+
 helper and 
regulatory T cells in adipose, and these cells influence glucose homeostasis, adipose 
hypertrophy, and obesity (238).  Macrophages are key players in the development of 
atherosclerosis.  NLRP3 inflammasome activation facilitated the dramatic uptake of 
lipids into bone marrow macrophage lysosomes (16).  ATP-stimulated NLRP3 
inflammasome activation resulted in high levels of cholesterol accumulation in the 
lysosome (16).  NLRP3 inflammasome activation also altered trafficking of intracellular 
lipids, which caused a buildup of sphingolipids in the lysosome (16).  The inflammasome 
increased macrophage migration in an IL-1β- and IL-18-independent manner.  The 
researchers hypothesized that inflammasome activation enable macrophages to invade the 
artery wall, where the formation of foam cells leads to atherosclerosis (16).  Activation of 
the NLRP3 inflammasome in macrophages plays a role in atherogenesis and adipose 
inflammation. 
 
C. Gaps in Knowledge 
dT3, aT3, and gT3 are structurally similar and may possess the same anti-
inflammasome properties.  dT3 is readily isolated from the annatto plant, and may 
represent a potential therapeutic compound for ameliorating diabetic complications.  The 
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well-delineated anti-oxidant, anti-inflammatory, and pro-apoptotic properties of 
tocotrienols make them an ideal candidate for inhibiting the NLRP3 inflammasome.  The 
NLRP3 inflammasome has been implicated in diabetes (17,113,121).  Tocotrienol 
supplementation improves blood glucose levels and other detrimental effects of T2DM 
(165,188).  Indeed, our lab has found that gT3 inhibits the NLRP3 inflammasome (233).  
gT3 supplementation in a mouse model improved diabetes outcomes (233). 
Tocotrienols have been established as having anti-inflammatory and anti-oxidant 
properties.  Tocotrienols lower pro-inflammatory cytokines, such as TNF (163,165), IL-
1β (166), IL-6 (167), and IL-8 levels (168).  Tocotrienols induce superoxide dismutase 
(160,161) and NADPH:quinone oxidoreductase and glutathione peroxidase (162), which 
enables tocotrienols to alleviate oxidative stress.  Though exact NLRP3 inflammasome 
activation mechanisms are yet to be fully elucidated, ROS production has been identified 
as a common factor in NLRP3 inflammasome activators (24,27).  ROS inhibtors have 
been shown repeatedly to inhibit NLRP3 inflammasome activation (25,59,72-74,87).  
ROS production causes the protein TXNIP to bind with NLRP3 inflammasome, and 
assist inflammasome activation (55).  Consequently, our lab investigated the role of 
tocotrienols in ROS production in inflammasome inhibition in macrophages.  
Tocotrienols have been demonstrated to inhibit NF-κB (164,165,175-180).  dT3 has been 
studied for its ability to lower NF-κB priming, particularly in cancer models (211-213).  
Our lab therefore determined whether tocotrienols played a role in inhibiting NF-κB 
activation in macrophages stimulated with LPS as a potential mechanism for 
inflammasome activation inhibition.  Macrophages are key immune cell players in the 
development of obesity-induced inflammation (121).  Macrophages are recruited to 
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adipocytes during metabolic dysfunction (236).  They present NLRP3 inflammasome 
activity and thus are an ideal model to study for reducing chronic low-grade 
inflammation (121).   
In this research project, the potential of tocotrienols to decrease NLRP3 
inflammasome activation in macrophages was studied.  NF-κB activation and ROS 
production were investigated as potential mechanisms for NLRP3 inflammasome 
inhibition. 
 
2.2. Central Hypothesis, Purpose, and Specific Aims 
A. Purpose of the Study 
The purpose of the study is to investigate the role of tocotrienols (dT3, aT3, gT3) on 
NLRP3 inflammasome activation in macrophages and determine potential mechanisms of 
action behind the relationship between tocotrienols and inflammasome, focusing on dT3. 
 
B. Central Hypothesis 
Tocotrienols (dT3, aT3, gT3) inhibit NLRP3 inflammasome activation and IL-1β 
secretion in macrophages by decreasing NF-κB activation and ROS production. 
 
C. Specific Aims 
a. Specific Aim 1 
Establish the role of dT3 on NLRP3 inflammasome activation and IL-1β production in 
macrophages and compare the effect of dT3 in NLRP3 inflammasome activation to other 
tocotrienol and tocopherol forms. 
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The hypothesis for this aim is that dT3 will dose-dependently decrease NLRP3 activation 
IL-1β in macrophages.  We hypothesize that dT3 and gT3, but not aT3 will inhibit 
NLRP3 inflammasome activation and IL-1β secretion in macrophages. 
 
b. Specific Aim 2 
Investigate whether tocotrienols (dT3, aT3, gT3) inhibit the NLRP3 inflammasome 
through inhibition of NF-κB signaling and ROS production 
We hypothesize that tocotrienols (dT3, aT3, gT3) inhibit NF-κB activation and lower 
ROS production in macrophages, resulting in the inhibition in NLRP3 inflammasome 
activation. 
 
2.3. Materials, Methods, and Experimental Design 
A. Materials 
Preparation of tocotrienols  
American River Nutrition (Hadley, MA, USA) provided dT3.  Carotech (Edison, 
NJ,USA) provided gT3; 90% purity and aT3; 90% purity.  The concentration was 
determined by measuring observance at 292 nm and 298 nm using Synergy H1 multi-
mode reader (BioTek), and comparing it to a standard.  dT3 was stored as 3.3 mM stock, 
gT3 and aT3 were stored as 1 mM stock solution prepared in dimethyl sulfoxide 
(DMSO), in 100 μL aliquots, at -20⁰C.  The stock was diluted to 1-10 μM at the time of 
treatment to iJ774 macrophages and raw 264.7 macrophages.  
Nigericin 
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Nigericin (a K
+
/H
+
 ionophore) derived from Streptomyces hygroscopicus was purchased 
from Sigma-aldrich. 6.5 mM Nigericin stock was prepared in ethanol and stored at 20°C. 
Lipopolysaccharide 
Lipopolysaccharide (LPS) from Escherichia coli 055:B5 was stored at 20°C and diluted 
with completed media immediately before treatment to iJ774 macrophages. 
J774 cells 
J774 (iJ774) macrophages were a generous gift from Dr. Hornung.  iJ774 iGLuc 
macrophages express IL-β-Gaussia Luciferase fusion construct (iGLuc).  Gaussia 
luciferase (GLuc) activity was detected using the BioLux GLuc assay kit (NEB Inc.) 
(according to manufacturer’s instructions) (239). 
Raw 264.7 Macrophage Cells 
Raw 264.7 macrophage cells are from Abselon murine leukemia virus-induced tumor, 
from an adult male BALB/c mouse.  Raw 264.7 macrophages were purchased from 
ATCC (TIB-71). 
 
B. Methods 
Cell Culture 
All cells were cultured either in completed media or Opti-MEM.  Cultured media 
consisted of Dulbecco's Modified Eagle Medium (DMEM) supplemented with 1.5 mM 
L-glutamine, sodium pyruvate, 10% fetal bovine serum (Gibco), and 5% 
penicillin/streptomycin.  Cells were maintained at 5% CO2 at 37 °C. 
Determination of Tocotrienol Concentration 
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Tocotrienol stock was diluted with dimethyl sulfoxide (DMSO).  Stock solution was 
diluted 25x, 50x, and 100x, then observance was measured at OD292 nm and OD298 nm 
using Synergy H1 multi-mode reader (BioTek).  Ethanol was used as the blank.  The 
extinction coefficient ε (the OD value of 1M) was used to calculate concentration per 
(163).  
OD292 ε aT3=3870 M-1cm-1 
OD292 ε dT3=3300 M-1cm-1 
OD298 ε gT3=4230 M-1cm-1 
Results were averaged for the final stock concentration. 
Reporter Assay for Inflammasome 
IL-β-Gaussia Luciferase fusion construct (iGLuc) activity was determined with the 
BioLux GLuc Assay kit (NEB Inc.) and read using a Synergy H1 multi-mode reader 
(BioTek). 50 μL of BioLux GLuc substrate solution (NEB Inc.) was added to 20 μL of 
each sample, and luminescence was measured using Synergy H1 multi-mode reader 
(BioTek), according to manufacturer’s instructions. 
Measurement of IL-1β Production 
Levels of IL-1β in the medium was determined with commercial ELISA kits from R&D 
Systems.  Manufacturer’s protocol was followed. 
Western blot 
Immunoblotting was performed to measure protein expression in samples.  To measure 
caspase-1 and iGLuc proteins in collected media, 24 µL of media were loaded into the 
gel.  For total cell extracts, cells were first with Hank’s Balanced Salt Solution (HBSS) 
and cell extract collected using ice-cold Radioimmune Precipitation Assay (RIPA) buffer 
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(89% RIPA, 10% phosphatase inhibitor, 1% proteinase inhibitor).  The isolate was 
sonicated, centrifuged, and protein concentration determined with bicinchoninic acid 
assay (BSA assay). 15 μg of each sample was loaded in a 10% sodium dodecyl sulfate-
polyacrylamide electrophoresis gels.  Wet transfer was used to transfer the gel to a 
polyvinylidene difluoride (PVDF) membrane. 5% non-fat milk in tris-buffered saline 
with tween-20 (TBST) was used as washing buffer.  Membrane was next washed with 
TBST and incubated with primary antibody overnight.  The next day, the membrane was 
washed with TBST, incubated with secondary antibody (anti-rabbit, -mouse, or –goat) for 
1 h, then washed with TBST.  Membranes were developed using chemiluminesence using 
ECL solution (PerkinElmer) with a FluorChem E system (Proteinsimple).  Polyclonal or 
rabbit monoclonal antibodies targeting p-JNK (Thr183/Tyr185), p-ERK(Thr202/Tyr204), 
t-ERK, and inhibitor of kappa B (IκBα) were purchased from  Cell Signaling Technology 
(Danvers, MA, USA).  Antibody targeting iGLuc was purchased from New England 
BioLabs (Ipswich, MA, USA).  Antibody targeting caspase-1 was purchased from 
Adipogen (San Diego, CA, USA).  Band intensity was determined using ImageJ 
software. 
Real time qPCR 
qPCR will be performed to analyze gene expression.  Cells were homogenized in Trizol 
reagent (Invitrogen).  mRNA was isolated using chloroform and isopropanol.  DNase 
(Mediatech) was used to remove any genomic DNA contamination.  mRNA was 
reprecipitated, and quantified.  Bio-Rad iSCRIPT cDNA synthesis kit was used to 
generate 100 µL cDNA, stored at -20°C.  SYBR green and forward and reverse primers 
were added to each sample cDNA.  QuantStudio 6 Flex System was utilized for qPCR.  
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Relative gene expression was calculated using the 2
−ΔΔCT
 method.  Gene expression was 
normalized to HPRT. 
Table 1: Forward and Reverse Primers 
Gene Forward  Reverse 
HPRT GCTATAAATTCTTTGCTGACCT
GCTG 
AATTACTTTTATGTCCCCTGTTGA
CTGG 
IL-18 GACAGCCTGTGTTCGAGGAT TGGATCCATTTCCTCAAAGG 
IL-1β GTCACAAGAAACCATGGCACA
T 
GCCCATCAGAGGCAAGGA 
NLRP
3 
ATGCTGCTTCGACATCTCCT AACCAATGCGAGATCCTGAC 
TNFα GGCTGCCCCGACTACGT ACTTTCTCCTGGTATGAGATAGCA
AAT 
 
Measurement of Reactive Oxygen Species Generation 
Cells were washed with HBSS with Ca
2+
 and Mg (1.5 mM calcium, 1 mM magnesium).  
MitoSOX reagent was dissolved in DMSO, then diluted in HBSS with Ca
2+
 and Mg for a 
5 µM solution.  Cells were incubated with MitoSOX for 10 minutes protected from light.  
It is a fluorogenic molecular probe that targets mitochondria and reacts with superoxide 
to emit fluorescence. 
Statistical Analysis 
Statistical analysis included student's t-test or one-way ANOVA with Tukey’s multiple 
comparison tests.  All statistical analyses were conducted by GraphPad Prism 6 (Version 
6.02).  Statistical significance was defined as p<0.05.  In figures, *p<0.05 , **p<0.01, 
***p<0.001 
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C. Experimental design 
a. Specific Aim 1  
Study 1: Investigate the effectiveness of varying doses of dT3 on inhibiting NLRP3 
inflammasome activation and IL-1β secretion.  The hypothesis is that dT3 will dose-
dependently decrease NLRP3 inflammasome activation and IL-1β secretion in 
macrophages 
 
Figure 6. Gaussia luciferase construct in iJ774 macrophage reporter cell line 
 
Study 1 Detailed Procedure: 
iJ774 macrophages were seeded to 24-well plate and cultured with Opti-MEM media 
(n=4).  Cells were pre-treated with 0.5, 1, 2.5 and 5 μM dT3 or DMSO (control).  After 
48 h, media was changed and 0.5, 1, 2.5 and 5 μM dT3 or DMSO was added.  The 
NLRP3 inflammasome was stimulated with 100 ng/mL LPS for 1 h.  NLRP3 
inflammasome was activated with 6.5 μM Nigericin for 1 h.  Media was collected and 
stored in -80°C freezer. 
Pro-caspase 1 cleavage to caspase-1 cleavage was analyzed using Gaussia luminescence. 
50 μL of Gaussia luciferase assay was added to 20 μL media and the luminescence was 
measured using the luminometer function of the Synergy H1 multi-mode reader 
(BioTek).  IL-1β levels in the media were determined using commercial ELISA kits from 
R&D System, following the manufacturer’s protocol.  Results reported in pg/mL.  
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Western blot using media collected was used to verify the presence of iGLuc and to 
measure caspase-1 in the media. 
 
Study 2: Compare the effectiveness in various tocotrienols (dT3, aT3, gT3) on NLRP3 
inflammasome activation and IL-1β secretion in macrophages.  The hypothesis for this 
study is that dT3 and gT3 will effectively inhibit NLRP3 inflammasome and IL-1β 
secretion, and aT3 will not inhibit NLRP3 inflammasome and IL-1β secretion in 
macrophages 
Study 2 Detailed Procedure: 
iJ774 macrophages were seeded to 24-well plate and cultured with Opti-MEM media 
(n=4).  Cells were pre-treated with 1 μM dT3, aT3, or gT3 or DMSO (control).  After 48 
h, media was changed and tocotrienols were added.  The NLRP3 inflammasome was 
stimulated with 100 ng/mL LPS for 1 h.  NLRP3 inflammasome was activated with 6.5 
μM Nigericin for 1 h.  Media was collected and stored in -80°C freezer. 
Pro-caspase 1 cleavage to caspase-1 cleavage was analyzed using Gaussia luminescence. 
50 μL of Gaussia luciferase assay was added to 20 μL media and the luminescence was 
measured using the luminometer function of the Synergy H1 multi-mode reader 
(BioTek).  IL-1β levels in the media were determined using commercial ELISA kits from 
R&D System, following the manufacturer’s protocol.  Results reported in pg/mL.  
Western blot using media collected measured the presence of iGLuc and to measure 
caspase-1 in the media. 
The hypothesis is that dT3 will block NF-ᴋB activation 
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b. Specific Aim 2: 
Study 1: Determine the effect of various doses of dT3 on NF-κB activation in raw 264.7 
macrophages.  The hypothesis is that dT3 would dose-dependently decrease NF-κB 
activation stimulated by LPS in macrophages 
Study 1 Detailed Procedure: 
Raw 264.7 macrophages were cultured in a 6-well plate in opti-MEM (n=3).  Cells were 
pre-treated with 1 or 2.5 μM dT3 or DMSO for 48 h.  NF-κB activation was stimulated 
with LPS (100 ng/mL) for 3 h.  qPCR as detailed earlier was used to measure gene 
expression of NLRP3, TNF-α, IL-1β, and IL-18.  Reference gene was HPRT. 
 
Study 2: Determine the effect of different tocotrienols (dT3, aT3, gT3) on NF-κB 
activation in raw 264.7 macrophages.  The hypothesis is that tocotrienols would inhibit 
NF-κB activation stimulated by LPS in macrophages 
Study 2 Detailed Procedure: 
Raw 264.7 macrophages were cultured in a 6-well plate in opti-MEM (n=3).  Cells were 
pre-treated with 1 μM dT3, aT3, or gT3 or DMSO for 48 h.  NF-κB activation was 
stimulated with LPS (100 ng/mL) for 3 h.  qPCR as detailed earlier was used to measure 
gene expression of NLRP3, TNF-a, IL-1β, and IL-18.  Reference gene was HPRT. 
Raw 264.7 macrophages were cultured in a 6-well plate in opti-MEM (n=2).  Cells were 
pre-treated with 1 μM dT3, aT3, or gT3 or DMSO for 48 h.  NF-κB activation was 
stimulated with LPS (100 ng/mL) for 30 minutes.  Total cell extract was isolated as 
detailed earlier for Western Blot.  Samples were analyzed for pERK, t-ERK, p-JNK, p-
p38, and p- IκBα. 
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Study 3: Investigate the ability of tocotrienols to diminish ROS production in 
LPS/Nigericin stimulated raw 234.7 macrophages.  The hypothesis is that dT3, aT3, and 
gT3 would lower ROS production in raw 234.7 macrophages activated by LPS/Nigericin 
Live Cell Imaging: 
Raw 264.7 macrophages were seeded 2.5x10^5 cells in 12 well plate, and pre-treated 
with DMSO or 1 µM tocotrienol (dT3, aT3, gT3) for 48 h (n=2).  Cells were treated with 
LPS (100 ng/mL) for 1 h.  Media was removed and cells washed with HBSS with Ca
2+
 
(1.5 mM) and Mg
2+
(1 mM). 5 µM MitoSOX solution (MitoSOX reagent dissolved in 
DMSO and diluted in HBSS with Ca
2+
and Mg
2+
) was added to cells and incubated 
protected from light for 10 minutes.  MitoSOX solution was removed, and 100ng/mL 
LPS plus 6.5 µM Nigericin with 1µM tocotrienols was added.  Cells were incubated 
away from light for 10 minutes.  Cells were washed with HBSS with Ca
2+
and Mg
2+
.  
Nuclei were counter-stained in blue using DAPI, and pictures were taken using the EVOS 
FL cell imaging microscope (ThermoFisher, Waltham, MA, USA) on 40X magnification. 
Fluorescence Quantification: 
Raw 264.7 macrophages were seeded 30,000 cells/well in a 96 well plate and pre-treated 
with DMSO or 1 µM tocotrienol (dT3, aT3, gT3) for 48 h (n=6).  Cells were treated with 
LPS (100 ng/mL) for 1 h.  Media was removed and cells washed with HBSS+ with 
Ca
2+
and Mg
2+
.  5 µM MitoSOX solution (MitoSOX reagent dissolved in DMSO and 
diluted in HBSS with Ca
2+
and Mg
2+
) was added to cells and incubated protected from 
light for 10 minutes.  MitoSOX solution was removed, cell are stimulated with media 
containing 100ng/mL of LPS with 6.5 µM Nigericin and 1µM tocotrienol.  Cells were 
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incubated away from light for 10 minutes.  Cells were washed with HBSS with Ca
2+
and 
Mg
2+
.  Fluorescence excitation and emission was measured at 510 nm and 580 nm by 
Synergy H1 multi-mode reader (BioTek). 
 
2.4. Experimental Design and Results 
A. dT3 inhibits NLRP3 inflammasome activation in iJ774 macrophages.  
To determine the impact of dT3 on inflammasome activation, NLRP3 
inflammasome reporter assay was conducted, iJ774 macrophages that stably overexpress 
an inflammasome reporter (239) were pretreated with increasing doses of dT3 (0-5 μM) 
or vehicle (DMSO) for 48 h.  Cells were primed with LPS for 1 h and the inflammasome 
was stimulated by adding nigericin.  Gaussia luciferase activity reflected caspase-1 
mediated pro- IL-1β cleavage and gauged NRLP3 inflammasome activation.  
Pretreatment with 0.5-5 μM dT3 significantly decreased NLRP3 inflammasome 
activation (Fig. 7A).  Consistent with decreased inflammasome activation, dT3 pre-
treatment strikingly lowered IL-1β secretion to medium in iJ774 macrophages (Fig. 7B).  
These data clearly revealed that 1 μM of dT3 effectively attenuated IL-1β secretion and 
NLRP3 inflammasome activation.   
To further confirm these results, we measured protein levels of caspase-1 and 
iGLuc in the medium.  iGLuc protein is secreted from macrophages upon caspase-1 
cleavage of pro-IL-1β.  Treatment with dT3 higher than 1 μM abolished iGLuc and 
caspase-1 secretion to the medium (Fig. 7C), suggesting almost complete blockage of 
inflammasome activation.  Band intensity quantification reflected this drastic decrease 
(Fig. 7D-E).  These results indicated that dT3 pretreatment suppresses LPS/nigericin-
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stimulated NLRP3 inflammasome activation, IL-1β production, and caspase-1 activity in 
iJ774 macrophages. 
 
B. Tocotrienols inhibit NLRP3 inflammasome activation in iJ774 macrophages.  
In a previous study, we demonstrated that gT3 was an effective suppressor of 
NLRP3 inflammasome activation in primary bone marrow derived macrophages as well 
as in iJ774 macrophages (239).  We next asked whether other tocotrienol forms, i.e., aT3, 
gT3, and dT3 that share the unsaturated side chain, inhibited NLRP3 inflammasome 
activation.  Since the majority of published studies used mixed tocotrienols, it would be 
useful to delineate the effectiveness of individual tocotrienol in inhibiting inflammasome 
activation. 
To address this, we pre-treated iJ774 macrophages with 1 μM dT3, α-tocotrienol 
(aT3), or γ-tocotrienol (gT3) or DMSO (vehicle) for 48 h.  Since 1 μM of tocotrienol is 
achievable in serum after oral intake of tocotrienol in humans (201,202), we chose 1 μM 
of individual tocotrienol as the pretreatment conditions.  iJ774 macrophages were first 
primed with LPS for 1 h and stimulated with nigericin for additional 1 h.  Gaussia 
luciferase activity revealed that all tocotrienols, i.e., dT3, aT3, gT3, were similarly 
effective in inhibiting NLRP3 inflammasome activation (Fig. 8A).  Unexpectedly, only 
dT3 and gT3, but not aT3, significantly diminished IL-1β secretion to the media as 
measured by ELISA (Fig. 8B).  aT3 tended to lower IL-1β secretion to the medium, but 
the difference did not reach statistical significance (Fig. 8B).   
To confirm the inhibitory effects of inflammasome by tocotrienols, secretion of 
caspase-1 and iGLuc protein to the media was measured.  We found that gT3 inhibited 
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caspase-1 and iGLuc secretion the most potently (Fig. 8C).  Band intensity confirmed 
that gT3 decreased caspase-1 and iGLuc protein levels the most potently.  Taken 
together, these results demonstrate that dT3, aT3, and gT3 pretreatment in macrophages 
inhibit LPS/nigericin- stimulated NLRP3 inflammasome activation, but shows a 
difference in potency as follows: gT3>dT3>aT3. 
 
C. dT3 decreases NF-κB activation in raw macrophages.  
After observing that dT3 inhibits NLRP3 inflammasome in macrophages, we 
investigated the underlying mechanisms.  The priming step of NLRP3 inflammasome 
involves NF-κB priming, which acts to provide transcripts of pro-inflammatory genes 
(49).  In our experimental setting, NF-kB activation occurs through TLR4 signaling, a 
pattern recognition receptor by LPS.  Literature suggests that dT3 inhibits NF-κB 
activation in cancer models (211-213). 
Thus, we first investigated the effect of dT3 on down-stream target genes of NF-
κB activation including NLRP3, TNF-α, IL-1β, and IL-18 mRNA gene levels.  Raw 
264.7 macrophages were pre-treated with vehicle control (DMSO), 1 or 2.5 µM of dT3 
for 48 h.  Cells were treated with LPS for 3 h to initiate NF-κB activation.  qPCR data 
showed that mRNA gene expression of Nlrp3, Tnf-α, and Il-1b was significantly 
decreased by 1 μM and 2.5 μM pretreatment of dT3 (Fig. 9A-C).  IL-18 mRNA 
expression was significantly lowered by pretreatment of 2.5 μM dT3 (Fig. 9D).  We 
concluded that 1 μM and 2.5 μM dT3 pre-treatment decreases pro-inflammatory NF-κB 
target gene expression when macrophages are primed with LPS. 
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D. Tocotrienols decrease NF-κB activation in raw macrophages.  
There is a body of evidence that aT3, gT3, and dT3 inhibit NF-κB activation in 
cancerous cells (164,165,175-180).  We therefore asked whether this property extended 
to macrophages.  Next, we wanted to determine the extent to which NF-κB inhibition by 
aT3, gT3 and dT3 contribute to the suppression of NLRP3 inflammasome in 
macrophages.  We pretreated raw 264.7 macrophages with 1 μM dT3, aT3, or gT3 or 
DMSO (vehicle) for 48 h, then stimulated with LPS for 3 h to induce NF-κB activation.  
Pretreatment with dT3, aT3, gT3 significantly decreased Nlrp3, Tnf-α, and Il-1b mRNA 
gene expression, measured by qPCR (Fig. 10 A-D).  Il-18 gene levels were significantly 
decreased by dT3 and gT3.   
To further confirm NF-κB inhibition by tocotrienol for down-regulation of 
NLRP3 inflammasome activation, we measured NF-κB signaling protein levels by 
Western blot analysis using total cell lysate (Fig. 10E).  IκBα is the cytosolic protein that 
sequestrates NF-κB from nuclear translocation and thereby inhibits NF-κB activation.  
IκBα was degraded when NF-κB priming was activated through LPS stimulation.  
Pretreatment with dT3 and gT3 protected from LPS-induced NF-κB activation.  Band 
intensity demonstrated that dT3 and gT3 significantly increased IκBα protein levels, 
whereas aT3 tended to increase IκBα, though this was not statistically significant (Fig. 
10F).  P-ERK was increased with LPS activation, whereas cells treated with dT3, aT3, 
and gT3 significantly down-regulated expression levels of P-ERK.  The decrease in P-
ERK levels due to pretreatment with dT3, aT3, and gT3 was statistically significant (Fig. 
10G).  JNK is inactivated with NF-κB activation (240).  P-JNK levels were significantly 
higher in the aT3, and gT3 pretreated groups, and lower in response to LPS stimulation 
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(Fig. 10H).  dT3 did not significantly lower P-JNK levels (Fig. 10H).   dT3 appears to 
lower NF-κB activation independent of P-JNK.   Taken together, these results confirmed 
that NF-κB activation is down-regulated in macrophages pre-treated with dT3, aT3, and 
gT3 and stimulated with LPS.  gT3 appears to be consistently the most effective at 
decreasing NF-κB-related gene expression and protein levels. 
 
E. Tocotrienols decrease ROS production in raw macrophages.  
Finally, we tested if tocotrienols inhibit NLRP3 inflammasome activation by 
lowering ROS production.  ROS is a common event that occurs in NLRP3 activation by a 
variety of stimulants (27).  Cassel et al. and Ding et al. (25,72) both reported that 
blockage of ROS production inhibited NLRP3 inflammasome activation.  Tocotrienols 
are powerful antioxidants—more powerful than tocopherols—which provides a rationale 
that tocotrienols attenuate NLRP3 inflammasome activation via inhibition of ROS 
production in macrophages (149-159,241-244). 
We pre-treated raw 264.7 macrophages with 1 μM dT3, aT3, or gT3 or DMSO 
(vehicle) for 48 h, primed with LPS for 1 h, and activated the inflammasome for 10 
minutes with nigericin.  MitoSOX was used to measure ROS production.  Nuclei were 
counter-stained in blue with DAPI (4',6-diamidino-2-phenylindole).  Inflammasome 
activation by LPS/nigericin treatment increased ROS production while pretreatment with 
dT3, aT3, and gT3 significantly attenuated MitoSOX red fluorescence suggesting that 
tocotrienols lowers ROS production (Fig. 11A).  To quantify this decrease in ROS, raw 
264.7 macrophages were pretreated with 1 μM dT3, aT3, or gT3 or DMSO (vehicle) for 
48 h, primed with LPS for 1 h, and activated the inflammasome for 10 minutes with 
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nigericin (Fig. 11B).  MitoSOX was used to measure ROS levels.  Quantification of red 
fluorescence revealed a significant decrease in ROS production when cells were 
pretreated with aT3 and gT3 (Fig. 11B).  dT3 pretreatment showed a trend to decrease in 
ROS production, but it was not significant (Fig. 11B).  Taken together, these results 
indicate that pretreatment with aT3, gT3, but a lesser extent with dT3, decrease ROS 
production during LPS/nigericin-mediated inflammasome activation in macrophages. 
 
2.5. Discussion 
A. Discussion 
The NLRP3 inflammasome is a multi-protein complex that is assembled in 
response to cellular stressors (13).  NLRP3 inflammasome activation results in the 
secretion of the inflammatory cytokines IL-1β and IL-18 (75).  It perpetuates chronic 
low-grade inflammation and is implicated in the development of insulin resistance (121), 
atherosclerosis (6), and liver steatosis (34) among many other inflammatory conditions.  
Tocotrienols are recognized as being anti-inflammatory and anti-oxidants, and dT3 is an 
easily isolated form of tocotrienol (147).  We therefore primarily aimed to determine 
whether dT3 inhibited NLRP3 inflammasome activation, and compare the inhibitory 
effect of dT3 on the NLRP3 inflammasome to other tocotrienol forms, i.e., aT3 and gT3.  
Secondly, we investigated potential mechanisms of NLRP3 inflammasome attenuation.  
In our model of tocotrienols and inflammasome activation, a priming signal (e.g. LPS, 
FFA) activates NF-κB signaling and increases pro-inflammatory gene expression (Fig. 8).  
The second signal consisting of DAMPs and PAMPs initiate the assembly and activation 
of the NLRP3 inflammasome and involves increased ROS production (Fig. 8).  
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Activation of the NLRP3 inflammasome leads to production of pro-inflammatory 
cytokines.  However, dT3, aT3, and gT3 inhibit the NF-κB priming signal and decrease 
ROS production in LPS/nigericin primed macrophages (Fig. 8). 
We chose macrophages as the model for NLRP3 inflammasome activation due to 
the involvement of the immune system, and in particular macrophages, in the 
development of obesity-related diseases.  Therefore, the inhibition of inflammasome 
activation in macrophages is potentially metabolically beneficial.  A high fat diet can lead 
to NLRP3 inflammasome activation in macrophages (121).  In addition, overweight and 
obesity leads to macrophage infiltration in the adipose and adipocyte inflammation (236).  
This suggests that high circulating levels of free fatty acids during a high fat diet and the 
overweight and obese states send a danger signal to macrophages.  The NLRP3 
inflammasome then becomes activated in the macrophages and they begin to infiltrate the 
adipose tissue where they perpetuate the inflammatory signal (130).  Adipose 
inflammation then leads to peripheral insulin resistance, which worsens as the chronic 
inflammation continues (130).  Therefore, we investigated the therapeutic potential of 
tocotrienols in alleviating the unwarranted activation of the NLRP3 inflammasome.   
We showed that pretreatment with 0.5-5 μM dT3 inhibits LPS/nigericin-induced 
NLRP3 inflammasome activation (Fig. 7).  This led to a decrease in IL-1β production and 
caspase-1 levels in macrophages (Fig. 7B-C).  This inflammasome-inhibitory effect 
extends to other tocotrienols.  dT3, aT3, and gT3 all inhibit NLRP3 inflammasome 
activation and IL-1β production in macrophages stimulated with LPS/nigericin (Fig. 8).  
We hypothesized that aT3 would not inhibit NLRP3 inflammasome activation based on 
earlier data that aT3 not to be effective at inhibiting NF-κB activation.  Therefore, we 
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were surprised that aT3 inhibited NLRP3 inflammasome activation and IL-1β secretion.  
To our knowledge, this is the first study demonstrating that aT3 and dT3 also have an 
inhibitory effect on NLRP3 inflammasome activation.  Besides mediating the 
development of insulin resistance, the NLRP3 inflammasome continues the inflammatory 
cascade in many auto-inflammatory conditions.  Therefore, these tocotrienols may have 
ameliorate aberrant inflammation in these conditions.  Because of the central role that 
macrophages in infiltrating adipose tissue and mediating adipocyte inflammation, 
inhibiting inflammasome activation in macrophages with tocotrienols may be beneficial 
in the chronic, low-grade inflammation present during overweight and obesity.  We next 
investigated potential mechanisms of NLRP3 inflammasome inhibition.  NF-κB 
activation is involved in the priming of the NLRP3 inflammasome (49).  ROS production 
has been implicated in many NLRP3 inflammasome activators (27). 
NF-κB inhibition by tocotrienols has been studied in various cancer cell models, 
but their role in inhibiting NF-κB priming in macrophages has not been clearly 
established.  TLR signaling leads to NF-κB activation, which up-regulates genes 
including NLRP3, TNF-α, IL-1β, and IL-18 and NF-κB, which ultimately increases 
activation of NLRP3 inflammasomes (3,26,49).  For example, LPS can signal through 
TLR4 (7).  Our results indicate that tocotrienols decrease NF-κB activation in 
macrophages, leading to NLRP3 inflammasome inhibition (Fig. 10).  1-2.5 μM dT3 
diminished down-stream gene targets of NLRP3 inflammasome activation including 
Nlrp3, Tnf-α, Il-1b, and Il-18 (Fig. 9).  dT3, aT3, and gT3 all inhibited up-regulation of 
the pro-inflammatory genes of Nlrp3, Tnf-α, Il-1b, and Il-18 (Fig. 10A-D).  Tocotrienol 
pretreatment maintained cytosolic levels of IκBα in LPS-primed macrophages.  From our 
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results, it appears that gT3 is the most potent inhibitor of NF-κB activation in 
macrophages.  This difference between tocotrienol forms may be due to the difference in 
the side chains. 
After determining the role of NF-κB priming, we asked whether tocotrienols 
inhibited ROS production during the assembly stage of NLRP3 inflammasome activation.  
ROS is one of many NLRP3 inflammasome activators (27).  Mitochondrial damage and 
ROS production is related to Ca
2+
 flux (94), and K
+
 efflux leads to damage to the 
mitochondria (28).  ROS play a role in the deubiquitination of basally expressed NLRP3 
inflammasome and subsequent activation (96).  ER stress can lead to increased ROS 
production (67).  In macrophages, tocotrienols appear to be anti-oxidants by lowering 
ROS levels.  We found that dT3, aT3, gT3 inhibit ROS production in LPS/nigericin-
stimulated macrophages (Fig. 11).  Live cell imaging demonstrated a decrease in ROS 
production by dT3, aT3, and gT3 in macrophages stimulated with LPS/nigericin (Fig. 
11).  Fluorescence quantification showed that only aT3 and gT3 significantly lowered 
ROS production.  Though dT3 diminished ROS production, it was not statistically 
significant.  gT3 appears to be the most effective at decreasing NF-κB activation and 
ROS production.  dT3’s inhibitory mechanism may rely more heavily on NF-κB 
inhibition, whereas aT3 is more potent at lowering ROS production.  These results 
demonstrate that tocotrienols can alleviate oxidative stress due to stimulation with LPS 
and nigericin. 
The result of NF-κB priming inhibition and diminishment of ROS production in 
macrophages was ultimately a decrease in IL-1β production.  The IL-1 cytokine family, 
and in particular IL-1β, is heavily studied due to its activity in auto-inflammatory 
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diseases (245).  White adipose tissue is a main site of IL-1Ra, the IL-1β receptor, and the 
level of IL-1Ra is up-regulated during obesity and inflammation (103).  This supports the 
hypothesis that adipose tissue is a key organ in mediating inflammation through IL-1β 
signaling during obesity (103).  IL-1β is implicated in the development of insulin 
resistance and the pathophysiology of T2DM (246).  High levels of IL-1β in pancreatic β-
cells promotes apoptosis and cell death, which may lead to insulin resistance and the 
development of T2DM (247).  Blocking IL-1β cytokine signaling has long been proposed 
as a mechanism for improving insulin sensitivity.  In KK-Ay mice, blocking IL-1β 
improved circulating levels of free fatty acids and triglycerides, lowered β-cell apoptosis, 
and ultimately improved glycemia and insulin signaling (248).  Decrease of IL-1β 
production in macrophages by tocotrienols could thus improve insulin resistance and 
mitigate adipocyte inflammation.  Addition of tocotrienols may also protect against β-cell 
death.   Tocotrienols could ameliorate the detrimental inflammatory response to a diet 
high in saturated fats. 
Chronic inflammation is implicated in the pathophysiology of many obesity-
related diseases.  The NLRP3 inflammasome is at the crux of this metabolic 
inflammation, and is involved in many auto-inflammatory diseases.  Decreasing aberrant 
inflammation may ameliorate these conditions.  Lower levels of secreted IL-1β are 
potentially beneficial for many chronic diseases, such as T2DM.  To our knowledge, this 
is the first study delineating the differential effects of the tocotrienols dT3, aT3, and gT3 
on NLRP3 inflammasome activation in macrophages.  Here, we have shown that 
tocotrienols effectively inhibit NLRP3 inflammasome activation and IL-1β production 
through attenuating NF-κB priming and ROS production suggesting that inclusion of 
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tocotrienol in the diet may constitute a practical approach to attenuate and/or prevent 
inflammation-mediated metabolic disorders, such as obesity and diabetes. 
 
B. Limitations and Future Studies 
There are several limitations to this study.  This was an in vitro study, so the 
results obtained from dT3 and aT3 treatment may not exactly translate in an in vivo 
model.  Furthermore, though measurement of IᴋBα protein degradation levels correlate 
with NF-ᴋB activation, determination of NF-ᴋB nuclear translocation more directly 
measures this priming step.  We were not able to correct MitoSOX fluorescence data for 
mitochondrial membrane potential, and this reagent only measures superoxide 
formation.  It would be useful to measure other types of ROS in the cells. 
A possible future study would be to measure ROS production through DCFDA, 
which captures a wider variety of ROS produced in the cell.  Other future studies could 
investigate the role of tocotrienols in ameliorating ER stress.  Tocotrienols may also 
decrease K
+
 efflux, or modulating Ca
2+
 which may inhibit NLRP3 inflammasome 
activation.  NLRP3 inflammasome activation is modulated through microRNA (97,98), 
and this is another mechanism that could be investigated.  Another possible study could 
examine the cross-talk between macrophages and adipose tissue, focusing on the effect 
on tissue inflammation and insulin signaling.  This study could also investigate adipose 
browning, adipogenesis, and glucose tolerance. 
Tocotrienols could be studied in many in vivo models of inflammatory conditions 
that involve the NLRP3 inflammasome.  These include as arthritis, gout, and Alzheimer’s 
disease.  In vivo models could test whether gT3 or a combination of tocotrienols are more 
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effective at ameliorating inflammation.  One study could examine whether a combination 
of tocotrienols or solely gT3 is more effective at ameliorating the adipose inflammation 
associated with a diet high in saturated fat.  This research could also investigate whether 
there are metabolic benefits to the liver.  Tocotrienols may affect liver inflammation and 
decrease NASH, since it is related to NLRP3 inflammasome activation.  In addition, 
adipose inflammation decreased adipocyte browning, so a study could investigate 
whether tocotrienols may facilitate the browning by inhibiting inflammation. An in vivo 
study could test whether tocotrienol supplements improves endothelial dysfunction in a 
model of cardiovascular diseases.  Potentially, human trials could investigate the efficacy 
of a tocotrienol supplement in attenuating NLRP3 inflammasome activation in adipose 
and the effect on insulin resistance and inflammation.  Tocotrienols could also be studied 
in a human trial investigating the benefit of tocotrienols in conditions associated with the 
NLRP3 inflammasome including gout, arthritis, or Alzheimer’s disease. 
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Figures 
 
 
Figure 7. dT3 inhibits NLRP3 inflammasome activation in iJ774 macrophages. iJ774 
macrophages were pre-treated with dT3 (0-5 μM) for 48 h, then primed with LPS (100 
ng/mL) for 1h and stimulated with Nigericin (nig) (6.5 μM) for 1 h. A: Relative Gaussia 
luciferase activity measured by luminometer. B: IL-1β secretion in supernatant, 
quantified by ELISA. C: Supernatant protein levels of GLuc fusion protein and cleaved 
caspase-1 detected through Western blot. D-E. Band intensity of caspase-1 and iGLuc 
Western blot, quantified by ImageJ. 
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Figure 8. Tocotrienols inhibit NLRP3 inflammasome activation in in iJ774 
macrophages. iJ774 macrophages were pre-treated with dT3, aT3, and gT3 (1 μM) for 
48 h, then primed with LPS (100 ng/mL) for 1h and stimulated with Nigericin (nig) (6.5 
μM) for 1 h. A: Relative Gaussia luciferase activity measured by luminometer. B: IL-1β 
secretion in supernatant, quantified by ELISA. C: Supernatant protein levels of GLuc 
fusion protein and cleaved caspase-1 detected through Western blot. D-E. Band intensity 
of caspase-1 and iGLuc Western blot, quantified by ImageJ. 
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Figure 9. dT3 decrease NF-κB activation in manner in raw macrophages. Raw 264.7 
macrophages were pre-treated with dT3 (0-5 μM) for 48 h, then primed with LPS (100 
ng/mL) for 3h. A-D: Gene expression measured through qPCR 
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Figure 10. Tocotrienols decrease NF-κB activation in raw macrophages. Raw 264.7 
macrophages were pre-treated with dT3, aT3, and gT3 (1 μM) for 48 h, then primed with 
LPS (100 ng/mL) for 3h. A-D: Gene expression measured through qPCR. E: Protein 
levels measured with Western Blot F-H. Band intensity of IᴋBα, P-ERK, and P-JNK 
Western blot, quantified by ImageJ. 
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Figure 11. Tocotrienols decrease ROS production in raw macrophages. Raw 264.7 
macrophages were pre-treated with dT3, aT3, and gT3 (1 μM) for 48 h, then primed with 
LPS (100 ng/mL) for 1 hour and activated with Nigericin (nig) (6.5 μM) for 20 minutes. 
Reactive oxygen species was detected using MitoSOX reagent.  A: Nuclei were stained 
blue.  Cell images were take using EVOS FL cell imaging microscope. B: Fluoresence 
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Figure 12. Proposed model that tocotrienols attenuate NLRP3 Inflammasome. An 
initial signal (e.g. LPS, FFA) signals through TLRs to induce NF-κB signaling (A) and 
increase pro-inflammatory gene expression (i.e. Nlrp3, Il-1β, Il-18, Tnf-α) (B).  PAMPs 
or DAMPs constitute the second signal (C) and induce ROS production (D), which 
initiates inflammasome assembly and activation (E).  This leads to caspase-1-mediated 
cleavage of IL-1β (F).  Tocotrienols (i.e. dT3, aT3, gT3) inhibit NF-κB activation, 
reducing pro-inflammatory gene expression (G).  As a secondary mechanism, 
tocotrienols inhibit ROS production, which attenuates the second activating signal for 
NLRP3 inflammasome assembly (H).  The proposed potency for tocotrienols on NLRP3 
inflammasome inhibition is gT3>dT3>aT3 (G,H).  Inhibition of NLRP3 inflammasome 
activation results in reduced production of the pro-inflammatory cytokine IL-1β (F). 
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APPENDIX 1: 
Abbreviations 
AMPK—AMP-activated protein kinase 
APAP—Acetaminophen  
ARRB2—Arrestin, Beta 2 
ASC—Apoptosis-associated speck-like protein containing CARD 
aT3—Alpha-tocotrienol 
ATF6—Activating transcription factor 6 
ATP—Adenosine triphosphate 
ATTP—α­tocopherol transfer protein 
ATM—Adipose tissue macrophages 
ATRvD1—Aspirin-triggered Resolvin D1 
BMDM—Bone marrow derived macrophages 
BSA— Bicinchoninic acid 
cAMP—Cyclic adenosine monophosphate 
CARD—Caspase activation and recruitment domain 
C/EPB—CCAAT-enhancer-binding protein 
CHOP—C/EBP homologous protein 
CLA—Conjugated linoleic acid 
COX—Cyclooxygenases 
CPPD—Calcium pyrophosphate dehydrate 
DAMP—Damage-associated molecular patterns 
DAPI—4',6-diamidino-2-phenylindole 
DHA—Docosahexaenoic acid 
DMEM—Dulbecco’s modified eagle medium 
DMSO—Dimethyl sulfoxide 
dT3—Delta-tocotrienol 
EGCG—Epigallocatechin-3-gallate 
EPA—Eicosapentaenoic acid 
ER—Endoplasmic reticulum 
ESRD—End-stage renal disease 
FFA—Free fatty acids 
FFAR4—Free fatty acid receptor 4 
FSGS—Focal segmental glomerulosclerosis 
G-CSF—Granulocyte colony-stimulating factor 
GPR—G-protein coupled receptor 
GRAS—Generally recognized as safe 
gT3—Gamma-tocotrienol 
HbA1c—Hemoglobin A1c 
HBSS—Hank’s balanced salt solution 
HFD—High-fat diet 
HK-2—Human kidney-2 
HMGB1—High mobility group box 1 
HMG-CoA—3-hydroxy-3-methylglutaryl-coenzyme A 
HOMA-IR—Homeostatic Model Assessment of Insulin Resistance 
HUVEC—Human umbilical vein endothelial cells 
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IFN-γ—Interferon-γ  
iGLuc—IL-1β-Gaussia Luciferase fusion construct 
IκBα—Inhibitor of kappa B 
IKK—IκB kinase 
IL-1β—Interleukin-1β 
IL-18—Interleukin-18 
iNOS—Inducible nitric-oxide synthase 
IRE1-α —Inducible nitric-oxide synthase 
JNK—Jun amino-terminal kinases 
LDL—Low-density lipoprotein 
LOX—Lipoxygenases  
LPS--Lipopolysaccaride 
LRR—Leucine-rich-repeat domain 
MAM—Mitochondria-associated ER membrane 
MAPK—Mitogen-activated protein kinases 
MCP-1—Monocyte chemoattractant protein-1 
MiR-223—MicroRNA-223  
mtDNA—Mitochondrial DNA 
MSU—Monosodium urate 
MUFA—Monounsaturated fatty acids 
NAC—N-acetyl-L-cysteine 
NADPH—Nicotinamide adenine dinucleotide phosphate 
NASH—Non-alcoholic steatohepatitis 
NF-κB—Nuclear factor κB 
NLRP3—NOD-like receptor family, pyrin domain containing 3 
NO—Nitric oxide 
oxLDL—Oxidized LDL 
P2x7R—P2X purinoceptor 7 
PAMP—Pathogen-associated molecular patterns PD1-- 
P-erk—Phospho-extracellular signal regulated kinase 
PERK—Protein kinase R-like endoplasmic reticulum kinase 
PPAR—Peroxisome proliferator-activated receptor 
P-gly—P-glycoprotein 
PRR—Pattern recognition receptors 
PUFA—Polyunsaturated fatty acids 
PVDF—Polyvinylidene difluoride 
RIPA—Radioimmune Precipitation Assay 
ROS—Reactive oxygen species 
qPCR—Quantitative reverse transcription 
RvD1—Resolvin D1 
SFA—Saturated fatty acids 
STZ—Streptozotocin 
TAP—α­tocopherol associated protein 
T2DM—Type 2 diabetes mellitus 
TBST—Tris-buffered saline with tween-20 
TLR—Toll-like receptor 
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TNF-α—Tumor necrosis factor α 
TRF—Tocotrienol rich fraction 
TRX—Thioredoxin 
TUDCA—Tauroursodeoxycholic acid 
TXNIP—Thioredoxin interacting protein 
UFA—Unsaturated fatty acids 
UPR—Unfolded protein response 
VAT—Visceral adipose tissue 
X/XO—Xanthine/xanthine oxidase 
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